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Herpes zoster, acute cardiovascular events and the role of zoster vaccination
C Minassian, S Thomas, L Smeeth, I Douglas, R Brauer and S Langan Faculty of Epidemiology 
and Population Health, London School of Hygiene and Tropical Medicine, London, United 
Kingdom
Herpes zoster is common, may have serious consequences and an effective vaccine is available. 
Emerging data suggests that there may be an increased risk of acute cardiovascular events following 
zoster. However, the majority of existing data are limited by residual confounding. No study has 
assessed the risk of acute myocardial infarction shortly after herpes zoster or the role of zoster 
vaccination in the association between zoster and acute cardiovascular events. Our objective was 
to quantify the effect of zoster on the short-term risk of acute cardiovascular events and to assess 
whether zoster vaccination might modify this effect. The self-controlled case series method was used 
to estimate rates of stroke and acute myocardial infarction in defined periods after herpes zoster 
compared to other time periods, within individuals. Participants were Medicare beneficiaries aged 
65 or older with zoster and either a stroke (n=42,954) or myocardial infarction (n=24,237) between 
January 2006 and December 2011. Age-adjusted incidence ratios for stroke and myocardial infarc-
tion during pre-defined periods up to 12 months after zoster relative to unexposed time periods were 
calculated using conditional Poisson regression. We observed a marked increase in the rate of acute 
cardiovascular events in the first week after zoster: a 2.4-fold increased stroke rate (IR 2.37, 95% 
CI 2.17-2.59) and a 1.7-fold increased MI rate (IR 1.68, 95% CI 1.47-1.92), followed by a gradual 
resolution over six months. The incidence ratio for stroke was reduced among zoster vaccinees 
during the first four weeks after zoster but no significant effect modification was observed. Stroke 
and MI rates are transiently increased after exposure to zoster and zoster vaccination may lessen 
the effect of zoster on stroke. These findings greatly enhance our understanding of the temporality 
and magnitude of the effect of zoster on acute cardiovascular events and highlight a potential role 
for zoster vaccination in reducing incident stroke after zoster.    
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Expression ability of RNAIII gene encoding δ-toxin in Staphylococcus aureus isolated from 
infant skin is associated with atopic dermatitis development
Y Nakamura,1 Y Inoue,2 Y Katayama,1 G Nunez,3 N Shimojo2 and H Matsue1 1 Dermatology, 
Chiba University, Chiba, Japan, 2 Pediatrics, Chiba University, Chiba, Japan and 3 Pathology, 
University of Michigan, Ann Arbor, MI
Atopic dermatitis (AD) is reportedly associated with colonization by S. aureus in the affected skin. 
We previously reported that δ-toxin released by S. aureus induced rapid and robust mast cell (MC) 
degranulation in vitro. In addition, colonization of the mouse lesional skin with S. aureus resulted 
in severe allergic skin inflammation, which was dependent on δ-toxin released by the bacteria and 
the presence of MCs in the skin. About 60% of AD patients reportedly develop the eruption in the 
first year of life. In a birth cohort that recruited 270 mother-child pairs, we found that 6-month old 
infants with S. aureus colonization on their cheek developed AD more frequently at 1 year old 
than the bacteria negative 6-month infants with higher AD odds ratio (odds ratio 4.203, p=0.008). 
To further clarify the virulency of δ-toxin in AD development, we examined RNAIII expression 
in S. aureus (n=132) strains isolated from 270 infant cheeks by qPCR. RNAIII, a regulatory RNA 
that is induced by the agr quorum-sensing of S. aureus, encodes δ-toxin. The expression of RNAIII 
in S. aureus isolated from 6-month old infants was associated characteristically with AD disease 
development at 1 year old. Other exotoxins, SEs and TSST-1, were not associated with AD disease 
development. RNAIII does not express constitutively, but is induced by agr quorum-sensing. This 
induction is mediated by a cell density-dependent signal transduction system, which controls a 
variety of the physiological behavior in bacteria. Therefore, we also examined RNAIII expression of 
S. aureus in the lesional and non-lesional skin of patients with AD. RNAIII expression was elevated 
only in the lesional skin but not in non-lesional skin of AD. These studies provide a mechanistic 
link between δ-toxin of S. aureus and AD, suggesting that δ-toxin may become a promising new 
preventive and therapeutic target in AD.    
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Baseline Expression of T Cell Receptor Gamma-V Gene Family is Associated with High Levels 
of Response to Ixekizumab Treatment in Psoriasis
JG Krueger,1 M Suarez-Farinas,1 A Beselin,2 D Ilo,2 R Hoffman,2 E Dow,2 E Nantz,2 
L Nisenbaum,2 K Schroeder2 and R Higgs2 1 Rockefeller U., New York, NY and 2 Lilly, 
Indianapolis, IN
A goal for new medical therapies is personalizing treatment by identifying those individual patients 
most likely to achieve the greatest benefit prior to clinical exposure such as through the use of a 
biomarker. To identify biomarkers that may predict future response to a therapy, we performed 
a hypothesis generating experiment comparing clinical outcomes in psoriasis to baseline mRNA 
expression using samples from a phase 2 study of ixekizumab, an anti-IL-17A monoclonal antibody. 
In a randomized, double-blind, placebo controlled trial, patients with chronic, moderate to severe 
plaque psoriasis were randomized to receive subcutaneous injections of ixekizumab at 150 mg 
(n=28), 75 mg (n=29), 25 mg (n=30), 10 mg (n=28) or placebo (n=27) at Weeks 0, 2, 4, 8, 12 and 
16. mRNA levels from whole blood samples were evaluated using Affymetrix HG-U133 Plus 2 
whole genome microarrays. Magnet bead isolation using a TRGV framework monoclonal antibody 
was used to isolate TRGV-positive cells. TRGV genes were analyzed by qPCR from patient samples 
along with controls. Clinical responses were measured using the psoriasis area and severity index 
(PASI). In the 75 mg and 150 mg groups at week 16, we observed significant differences in baseline 
mRNA expression of TRGV in patients achieving a PASI 90 or PASI 100 compared to those that did 
not (p=0.007 and p=0.003, respectively). These results were confirmed using qPCR. These results 
suggest that the level of mRNA expression for TRGV at baseline may help predict clinical response 
to ixekizumab treatment. Furthermore, while inflammation and epidermal hyperplasia in psoriasis 
are thought to be controlled by Th17-derived cytokines, with IL-17A having a central role in the 
disease, these data suggest that innate lymphoid cells expressing TRGV may also have a role in the 
immune pathogenesis of psoriasis.    
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A comprehensive omics assessment of etanercept therapy for psoriasis
A Foulkes,1 N Rattray,1 M Pirmohamed,4 R Goodacre,1 NJ Reynolds,5 MJ Donaldson,3 
M Barnes,2 CE Griffiths1 and R Warren1 1 University of Manchester, Manchester, United 
Kingdom, 2 Centre for Translational Pharmacogenomics, Queen Mary University London, 
London, United Kingdom, 3 GlaxoSmithKline, Uxbridge, United Kingdom, 4 The University 
of Liverpool, Liverpool, United Kingdom and 5 Department of Cellular Medicine, Newcastle 
University, Newcastle upon Tyne, United Kingdom
Pharmacogenomics holds promise for biomarker discovery and mechanistic insight into the per-
sonalisation of therapies for psoriasis. We present a pharmacogenomic characterisation of 10 
psoriasis patients receiving etanercept therapy. We performed analysis of the genome through 
genome-wide association study, transcriptome through RNA sequencing and metabolome through 
three validated technologies. Participants underwent detailed phenotyping and were assessed for 
response to therapy using the Psoriasis Area and Severity Index (PASI). Blood, skin biopsies (lesional 
and non-lesional) and urine samples were collected at three time points. RNA sequencing was 
conducted on RNA extracted from paired lesional and non-lesional skin samples (n = 60) and 
on total RNA and miRNA extracted from blood samples (n = 30). Metabolomic assessment was 
carried out on serum and urine samples. Differential expression between responders and non-re-
sponders at 12 weeks of therapy identified 118 transcripts from analysis of lesional sample data 
and identified 295 transcripts from analysis of lesional and non-lesional sample data (p < 0.05, 
corrected for multiple testing). Comparison of lesional and non-lesional skin sample data reflects 
many known mediators of the immune-inflammatory processes that characterise psoriasis. Hierar-
chical clustering of differentially expressed genes also identified novel genes that appeared to show 
co-regulation with known psoriasis genes, offering new insights into mechanisms of disease and 
drug response. Metabolomic assessment demonstrated clustering of metabolite profiles from urine 
and serum samples across multiple technologies. Psoriasis is a model disease for the development 
of pharmacogenomic markers of treatment response. We have identified pathways that may play a 
role in dictating therapeutic response in psoriasis.    
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Risk of Death in Bullous Pemphigoid: a Retrospective Database Study in Finland
A Försti,1 J Jokelainen,2 M Timonen3 and K Tasanen1 1 Department of Dermatology, Oulu 
University Hospital, Oulu, Finland, 2 Unit of General Practice, Oulu University Hospital, 
Oulu, Finland and 3 Institute of Health Sciences, University of Oulu, Oulu, Finland
The aim of this study was to investigate, firstly, the standardized mortality ratio (SMR) of bullous 
pemphigoid (BP) patients in Finland, and secondly, the concomitant comorbidities and medications. 
This was a retrospective, cross-sectional database study of the records of all BP cases diagnosed at 
the Department of Dermatology at Oulu University Hospital, Finland, between 1985 and 2012. We 
found 198 immunologically confirmed BP cases with the mean age of 77.5 years: 51.5% females 
and 48.5% males. The 1-year mortality was 16.7% and the SMR 7.56 (95% CI 4.98-10.14). The 
most common comorbidities were cardiovascular diseases (76.3%) and neurodegenerative diseases 
(40.9%). Polypharmacy was common, and it was significantly associated with increased mortality. 
The first line treatments used were oral prednisolone (62.6%), topical corticosteroid alone (29.8%), 
and tetracycline (7.6%). To compare the effect of treatment on mortality we divided BP patients 
into three groups. Group 1 (100 patients) was treated solely with oral prednisolone (together with 
topical corticosteroids), group 2 (40 patients) with topical corticosteroids with or without oral 
tetracycline, and group 3 (26 patients) with oral prednisolone and adjuvant immunosuppressant: 
azathioprine and/or methotrexate. Group 1 had the lowest 1-year survival. Groups 2 and 3 seemed 
to have similar prognosis, and were combined in the statistical analysis due to the small number 
of cases. When group 1 was compared with the combined groups 2 and 3, the patients in group 1 
had 2.3-fold increased risk of death within one year after the diagnosis (HR=2.3, 95%CI 1.0-5.4, 
p=0.053). When the result was adjusted for age and sex, HR was 2.2 (95% CI 0.9-5.1, p=0.073). 
In conclusion, BP patients have elevated mortality compared with general population of the same 
age, and it can be partly caused by the medications used to treat BP.    
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Cancer in neurofibromatosis 1
S Peltonen,1 E Uusitalo,2 M Rantanen,3 R Kallionpää,2 M Pöyhönen,4 J Leppävirta,1 
J Pitkäniemi3 and J Peltonen2 1 Department of Dermatology, University of Turku and Turku 
University Hospital, Turku, Finland, 2 Department of Cell Biology and Anatomy, University of 
Turku, Turku, Finland, 3 Finnish Cancer Registry, Helsinki, Finland and 4 Helsinki University 
Hospital, Helsinki, Finland
Neurofibromatosis Type 1 (NF1) is well known to cause cancer, primarily malignant peripheral 
nerve sheath tumors and intracranial gliomas. Based on these findings, NF1 can be called cancer 
syndrome. We present data to suggest a broader, more general cancer predisposition for NF1. The 
population-based Finnish NF1 cohort contained 1,404 patients with NF1 diagnosis verified from 
their medical records from 1987 to 2011. Total number of person years was 19075.2, with median 
follow up of 13.6 years. The NF1 cohort was cross-referenced with the Finnish Cancer Registry to 
correlate new cancer events and all deaths 1987-2012, and estimate standardized incidence ratios 
(SIR) and standardized mortality ratios (SMR). Survival was considered in terms of cancer type, 
age, gender and diagnosis year. These results suggest that NF1 syndrome is associated with a high 
risk of developing a variety of cancers and dying from them. The study revealed novel findings: 1) 
The early age of onset, female gender excess and high mortality; 2) excessive, early and aggressive 
breast cancer and excessive carcinomas of selected other types; 3) an excess of NF1 patients with 
two to three sequential cancers of different varieties. The material presented here gives new ways 
of considering NF1 germinal and somatic mutations as contributory to human cancer in general. 
These new considerations are likely to be important far beyond the NF1 syndrome itself. The 
results also show that NF1 is a life threatening disease and the patients require lifelong follow-up.   
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Quantification of risk factors for postherpetic neuralgia in a cohort of herpes zoster patients
H Forbes, K Bhaskaran, S Thomas, L Smeeth, T Clayton, K Mansfield, C Minassian and 
S Langan Faculty of Epidemiology and Population Health, London School of Hygiene and 
Tropical Medicine, London, United Kingdom
Herpes zoster commonly causes disabling neuropathic pain called postherpetic neuralgia. We 
aimed to investigate risk factors for postherpetic neuralgia. Using primary care data from the Clinical 
Practice Research Datalink, we fitted multivariable logistic regression models to investigate potential 
risk factors for postherpetic neuralgia (defined as pain ≥90 days after zoster, based on diagnostic and/
or prescription codes), including demographic characteristics, co-morbidities, and characteristics of 
the acute zoster episode. We also assessed whether their effects were modified by antiviral use. Of 
119,413 zoster patients, 6,956 (5.8%) developed postherpetic neuralgia. Postherpetic neuralgia risk 
rose steeply with age, most sharply between 50-79 years (adjusted odds ratio for a 10-year increase, 
1.71, 99% confidence interval 1.63-1.78). Postherpetic neuralgia risk was higher in women (6.3% 
vs 5.1% in men:OR=1.19, 1.10-1.28); and those with severely immunosuppressive conditions, 
including leukaemia (14.4%: 2.07, 1.08-3.96) and lymphoma (12.1%: 2.45, 1.53-3.93); autoim-
mune conditions, including rheumatoid arthritis (9.1%: 1.21, 0.99-1.46); and other comorbidities 
including asthma and diabetes. Ex-smokers also had an increased risk (7.1%: OR vs never-smokers 
=1.14, 1.05-1.24) as did underweight individuals (8.7%: OR vs healthy weight=1.25, 1.01-1.54). 
Antiviral use was not associated with postherpetic neuralgia (OR=1.04, 0.97-1.11). However the 
increased risk associated with severe immunosuppression appeared less pronounced in patients 
given antivirals. Postherpetic neuralgia risk increased with age and among those with severe immu-
nosuppression, who remain contraindicated for zoster vaccination.    
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Prospective controlled studies on the routine use of a novel multivariant ELISA for the diag-
nosis of autoimmune bullous diseases
N van Beek,1 C Dähnrich,2 N Hornig,2 S Lemcke,1 S Goletz,1 J Dworschak,1 D Zillikens,1 
W Schlumberger,2 E Schmidt1 and I Autoimmune Bullous Diseases Study Group*3 1 
Department of Dermatology, University of Luebeck, Luebeck, Germany, 2 Institute 
of Experimental Immunology,Euroimmun AG, Luebeck, Germany and 3 International 
Autoimmune Bullous Disease Study Group
The value of a novel multivariant ELISA (that allows the simultaneous testing for autoantibodies 
against BP180 NC16A, BP230, collagen type VII, desmoglein 1 and 3, and envoplakin) in the routine 
diagnosis of autoimmune bullous diseases (AIBD) has been probed in two prospective studies. In the 
multicenter study, consecutive sera from AIBD patients with positive direct IF microscopy (n=204) 
and in a single center study, consecutive sera from patients with suspicion of AIBD (n=289) were 
compared with the conventional multistep approach including IF microscopy of various substrates 
and immunoblotting of cellular extracts. In both studies, a high agreement was found between 
the multivariant ELISA and the conventional approach with 41 (20.1%) and 22 (7.6%) sera being 
discrepant in the multicenter and single center study, respectively. The highest agreement was 
found in patients with pemphigus (n=73 and n=11) with only 1(1.4% and 8.3%) discrepant serum 
in each cohort. 17 (47.3%) and 13 (56.5%) of the divergent results in the pemphigoid disorders 
were attributed to the lack of target antigens (e.g. p200 antigen, laminin 332, BP180 ectodomain) 
and the restriction to IgG reactivity in the multivariant ELISA. In summary, the multivariant ELISA is 
a novel and practical single-step tool that allows the rapid diagnosis of pemphigus diseases and the 
great majority of pemphigoid disorders. *Antalya, Turkey (S. Uzun); Belgrade, Serbia (L. Medenica); 
Bern, Switzerland (M. Horn); Poznan, Poland (M. Dmochowski); Rome, Italy (G. DiZenzo); Sofia, 
Bulgaria (K. Drenovska, S. Vassileva); Sydney, Australia (D. Murrell); Tel Aviv, Israel (E. Sprecher); 
Thessaloniki, Greece (A. Patsatsi); Warsaw, Poland (C. Kowalewski)    
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Gross cystic disease fluid protein 15 as a potential marker for decreased sweating in atopic 
dermatitis
K Kamiya, J Sakabe, H Yamaguchi, T Suzuki, T Yatagai, M Aoshima, T Ito and Y Tokura 
Department of Dermatology, Hamamatsu University School of Medicine, Hamamatsu city, 
Japan
It has been well known that eccrine sweating is dysregulated and reduced in patients with atopic 
dermatitis (AD). Gross cystic disease fluid protein 15 (GCDFP15) is expressed in normal exocrine 
organs, such as sweat, salivary and lacrimal glands. We have reported by using proteome analysis 
that the amounts of GCDFP15 are decreased in stratum corneum (SC) samples from AD patients 
(JACI, 2014). The aim of this study was to evaluate GCDFP15 production by eccrine glands with 
SC samples and to assess sweating in AD. SC samples were obtained from 51 healthy controls 
(HC) and 51 AD individuals, and proteins were extracted by our previously reported procedure. 
Sweat samples were from 18 HC and 12 AD subjects. GCDFP15 in SC and sweat was quantified 
by ELISA. The amounts of GCDFP15 in the SC extracts were significantly lower in AD than HC (P 
< 0.0001). The sweat samples from AD patients also had lower levels of GCDFP15 concentration 
(P < 0.05). The eccrine sweat apparatus consists of eccrine gland secretory coil, dermal duct, and 
acrosyringium. Immunohistochemistry showed positive GCDFP15 staining in the eccrine gland 
secretory cells and the ductal and acrosyringial lumen in normal skin, but AD lacked clear staining. 
To identify GCDFP15-producing cells, double immunofluorescence staining for GCDFP15 and S100 
protein was performed in frozen sections. The results showed that GCDFP15 was co-expressed with 
S100 protein, suggesting that the clear cell of eccrine glands produces GCDFP15. To address the 
mechanism underlying the decreased eccrine sweating in AD patients, we examined the expression 
of cholinergic receptor M3 (CHRM3), a receptor for acetylcholine-induced sweating, in eccrine 
sweat glands. The expression of CHRM3 was depressed in AD, suggesting contribution to the low 
sweating. In conclusion, this study showed that the SC of AD patients contained a low amount of 
GCDFP15 due to both low sweating and low GCDFP15 concentration in the sweat. GCDFP15 in 
SC could be a possible marker of eccrine sweating for AD.    
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Elongated microparticle penetration profiling reveals potential for enhanced transepidermal 
drug delivery in distict body sites despite differences in strata composition
T Prow, T Liu, H Soyer and M Ardigo Dermaology Research Centre, University of 
Queensland, Brisbane, QLD, Australia
Elongated microparticles are a recently developed technology to enhance topical drug delivery. 
Topical treatment is an attractive management approach for treating skin lesions. Unfortunately, 
many potentially therapeutic drugs have poor skin penetration profiles. We have developed and 
patented a novel platform for field- or lesion-directed drug delivery based on high-aspect ratio 
microparticles that were engineered to only penetrate the stratum corneum and viable epidermis. 
These microparticles are applied by massaging the material, with the active ingredient, into the skin. 
In these studies we utilize clinical reflectance confocal microscopy to show elongated microparticle 
penetration profiles in healthy skin, palm and in skin with dense hair coverage. We also compare 
chemokine profiles of elongated microparticle treated volunteer skin using our microbiopsy skin 
microsampling technology. Our results show that the primary barrier to elongated microparticle 
penetration is the dermal network of collagen and elastin. Mouse and volunteer data support the 
hypothesis that elongated microparticle treatment induces erythema but does not induce the typical 
inflammatory responses seen in chemical irritant exposure, i.e. sodium lauryl sulfate. Together, these 
data support the use of elongate microparticles to enhance delivery through the viable epidermis 
in a minimally invasive manner.    
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Serum IL-17A at baseline correlates with clinical response to tofacitinib and etanercept in 
moderate to severe psoriasis
G Berstein,1 W Zhang,1 C Soderstrom,2 S Fraser,2 J Lee,1 A Quazi,1 R Wolk,3 C Mebus,3 
H Valdez3 and L Fitz1 1 Pfizer Biotherapeutics, Cambridge, MA, 2 Pfizer PDM, Groton, CT 
and 3 Pfizer Global Innovative Pharma, New York, NY
Psoriasis is an inflammatory skin disease with systemic involvement. This study aimed to evaluate 
correlations between effects on circulating cytokines and chemokines and clinical efficacy in pso-
riasis patients (pts) treated with tofacitinib or etanercept. Tofacitinib is an oral JAK inhibitor that 
is being investigated for psoriasis. Etanercept is a TNFa blocker used in the treatment of psoriasis. 
Serum concentrations of IL-17A, IL-17AF, E-Selectin, IL-8, IP-10, MIG, MIP-1b, MIP-3b and TARC 
were determined at Week 0, 4 and 12 in pts with moderate to severe psoriasis treated with placebo 
(n=60), tofacitinib 5mg PO BID (n=184), tofacitinib 10mg PO BID (n=189) or etanercept 50mg SC 
BIW (n=190). IL-17A and IL-17AF were measured by Singulex Erenna immunoassays, while the 
other analytes were measured in one custom multiplex assay from Meso-Scale Discovery. Only 
IL-17A showed clear correlation with clinical response. Serum IL-17A decreased by 57.1% in pts 
achieving a PASI75 response at w12, but decreased only by 15.9% in non-responders. Although 
etanercept and tofacitinib 10mg had the same PASI75 response rate, the decrease in IL-17A was 
somewhat greater with etanercept (64.1% etanercept vs 53.6% tofacitinib 10mg, p=0.0045), which 
may suggest a different contribution of IL-17A reduction to the clinical efficacy of the two drugs. 
Serum levels of IL-17A at w0 showed moderate correlation with disease severity with Spearman 
correlation coefficient of 0.43. In PASI75 responders IL-17A at w12 was comparable between the 
two treatments (0.24-0.27pg/ml), but IL-17A at w0 was higher in the etanercept (0.76pg/ml) than 
in the tofacitinib cohort (0.56–0.59pg/ml). In contrast, in pts who did not achieve PASI75, IL-17A 
was higher in the tofacitinib (0.65–0.77pg/ml w0, 0.61–0.62pg/ml w12) than in the etanercept 
cohort (0.53pg/ml w0, 0.37pg/ml w12). These observations suggest that serum IL-17A w0 may be 
predictive of clinical response to treatment w12 with these agents.    
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The Effect of Prednisolone Treatment on the Expression of Glucocorticoid Receptors GRalpha 
and GRbeta in Bullous Pemphigoid
ME Kubin,1 PM Hägg,1 N Kokkonen,1 K Haapasaari,2 T Uchida,3 V Glumoff,3 P Kulmala,4 
T Hurskainen1 and K Tasanen1 1 Dermatology, MRC Oulu, Oulu University Hospital and 
University of Oulu, Oulu, Finland, 2 Pathology, MRC Oulu, Oulu University Hospital and 
University of Oulu, Oulu, Finland, 3 Microbiology, MRC Oulu, Oulu University Hospital and 
University of Oulu, Oulu, Finland and 4 Pediatrics, MRC Oulu, Oulu University Hospital and 
University of Oulu, Oulu, Finland
Bullous pemphigoid (BP) is the most common autoimmune blistering disease. The first line treat-
ments of BP are topical and/or systemic glucocorticoids (GC). The actions of GCs are mediated by 
glucocorticoid receptor (GR). GR exists in many isoforms, of which GRalpha and GRbeta are the 
most important. Here we have analysed the expression levels of GRalpha and GRbeta in BP, and 
also investigated whether the expression of GR isoforms is altered during prednisolone treatment. 
The expression level of GR isoform mRNAs in peripheral blood mononuclear cells (PBMC) isolated 
from BP patients and controls were quantitated using qPCR. GRalpha was present in all 16 BP and 17 
control samples, the expression of GRbeta was detected in 13 BP and 12 control samples. Western 
blot analysis of PBMC lysates showed the presence of GRalpha in all patient and control samples, 
whereas GRbeta was detected only in few samples. In addition, the expression of GRalpha and 
GRbeta was confirmed by immunohistochemical staining of lesional skin biopsies of BP samples 
and flow cytometric analysis of PBMC. To analyze the effect of prednisolone on the expression of 
GR isoforms in BP, GR isoform mRNA levels were measured from PBMC samples taken on days 
5, 14 and 60 after the initiation of prednisolone. On days 5 and 14 no constant changes in the 
expression of GR isoforms were detected, but on day 60, the expression of GRalpha was increased 
in majority of BP patients and GRbeta was decreased more than half of the BP patients. In summary, 
we report that patients with BP express both GR isoforms and that the expression is altered during 
systemic glucocorticoid treatment. GRbeta expression varied significantly and was not suitable as 
a clinical marker of GC sensitivity in BP patients.    
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A multicenter, randomized, single-blind study of topical clindamycin 1%/benzoyl peroxide 
5% once-daily fixed dose combination gel (Duac) vs. clindamycin 1% twice-daily gel in 
treatment of Chinenes acne vulgaris patients
J Xu,2 Q Lu,1 J Huang,3 Q Sun,4 F Hao,5 J Gu,6 H Fang,7 X Dong,8 J Li9 and A Hamedani9 1 
Second Xiangya Hospital, Changsha, China, 2 Huashan Hospital, Shanghai, China, 3 Third 
Xiangya Hospital, Changsha, China, 4 PUMH, Beijing, China, 5 Third Military Medical 
School, Chongqing, China, 6 Changhai Hospital, Shanghai, China, 7 Zhejiang Medical School 
First Hospital, Hangzhou, China, 8 Guangdong General Hospital, Guangzhou, China and 9 
GSK, Shanghai, China
Acne vulgaris affects up to 54% of Chinese adolescents. Combination therapy targets multiple etio-
logical factors involved in the disease pathogenesis, and has become the recommended standard of 
care for acne. Clindamycin (1%) and benzoyl peroxide (5%) (CDLN/BPO) fixed dose combination 
gel has been approved for acne in many countries. The purpose of this study was to support the 
registration of CDLN/BPO in China. To compare the efficacy and safety of CDLN/BPO once daily gel 
with clindamycin (1%) (CDLN) twice daily gel in Chinese patients with mild to moderate acne, 1016 
patients with mild to moderate acne were randomized (1:1) to receive CDLN/BPO gel once daily 
(n=500) or CDLN gel (n=516) twice daily for a 12-week treatment period and received at least one 
dose of treatment. Assessments included lesion counts (total, inflammatory and non inflammatory), 
global improvement scores, quality of life and safety. CDLN/BPO gel showed significantly greater 
percent reduction (p=0.003) from baseline in total lesion count, with significantly (p<0.05) higher 
proportion of patients showing a ≥2-grade improvement in Investigator’s Static Global Assessment 
score at week 12, compared with CDLN gel. Significant improvements in inflammatory and non 
inflammatory lesion counts were noted from week 1 of CDLN/BPO gel treatment, indicating rapid 
onset of action. The incidence of AEs in the CDLN/BPO group (14.4%) was numerically higher 
than that in the CDLN group (7.9%) and mainly included events related to application site reactions 
most likely attributed to BPO. CDLN/BPO gel demonstrated superior efficacy over CDLN gel along 
with acceptable tolerability in Chinese patients with mild to moderate acne.    
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Immunogenetics of non-melanoma skin cancer/pre-cancer in HIV
SI Goolamali,1 R Meys,1 T Shim,1 S Mletzko,2 F Fowles,3 F Tavarozzi,3 F Gotch,2 S Marsh,3 
C Harwood4 and C Bunker1 1 Dermatology, Chelsea and Westminster Hospital, London, 
United Kingdom, 2 Immunology, Chelsea and Westminster Hospital, London, United 
Kingdom, 3 Anthony Nolan Laboratories, The Royal Free Hospital, London, United Kingdom 
and 4 Blizard Institute, QMUL, London, United Kingdom
Immunogenotype (HLA type), is important in HIV dermatology, determining susceptibility to pso-
riasis and drug reactions. HLA associations with some squamous cell carcinomas (SCC) including 
cervical and with post-transplant non-melanoma skin cancer (NMSC) have been published, but 
HLA has not been hitherto investigated in HIV NMSC. We believe we have performed the first case/
control study investigating a possible role for immunogenotype in NMSC/pre-cancer pathogenesis 
in both HIV+ve and HIV-ve subjects. 58 HIV+ve (cases) and 58 HIV-ve (controls) patients with 
NMSC – basal cell carcinoma (BCC), SCC and penile SCC and pre-cancer- squamous cell carcinoma 
(SCC)-in situ (CIS), actinic keratoses (AKs) and penile pre-cancer (PCIS) were recruited. DNA was 
extracted from blood and a Luminex-based molecular HLA typing system used for typing. Excluding 
non-Caucasians, 49 cases and 58 controls were analysed using a technique of allele counting. For 
categorical data, Yates’ corrected chi-squared test or Fisher’s exact two-tailed test were utilised; 
Bonferroni corrections (BC) for multiple statistical testing. HLA-A*02 was more common in HIV+ve 
cases with NMSC/pre-cancer compared with controls (p-value=0.03) but statistical significance 
was lost with BC. HLA-DRB4*01, HLA-DQA1*01 and HLA-DQA1*03 were more common in 
controls (p-values=0.046, 0.009 and 0.012 respectively), but after BC, only HLA-DQA1*01 was 
statistically significant (corrected p-value=0.04). Other alleles of potential interest were HLA-B*14 
(p-value=0.06 before BC) and HLA-C*08 (p-value=0.06 before BC). Both were found with a higher 
frequency in cases and interestingly have been previously mooted to delay HIV progression in Euro-
pean populations. In summary, different HLA alleles that may be relevant to an immunogenotypic 
basis for NMSC have been identified in the two patient cohorts. However greater patient numbers 
are required to investigate this further.    
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Compounds Screening in Dosed Human Skins by Quantitative Mass Spectrometry Imaging
D Bonnel,1 S Ghilini,2 R Legouffe,1 C Verrier,2 G Picard-de Muller,1 M Cuadrado,2 
F Pamelard,1 G Hamm,1 A Heron1 and J Stauber1 1 ImaBiotech, Lille, France and 2 Galderma, 
Sophia-Antipolis, France
Combination of images from standard histology microscopy and quantitative mass spectrometry 
imaging (QMSI) allows the correlation of compound distribution and concentration within his-
tological structures of the skin. This new quantitative multi-imaging approach was applied on 
human fresh tissues after topical application on 2cm2 during 16 hours with a mixture of three test 
compounds (cassette-dosing) on Franz cells. Two LCMSMS approaches were used for comparing 
and validating QMSI results: firstly stratum corneum, epidermis and dermis were isolated and 
directly analysed by LCMSMS, and secondly 50 cryosections were extracted by organic solvent 
before LCMSMS analysis. The molecular images generated by QMSI on these skin tissue sections 
were used to clearly compare the penetration of each drug and confirm their concentration in the 
dermis in order to select the best candidate. QMSI combined with classical histological techniques 
was confirmed to be an essential multimodal approach in early clinical study for correlating clinical 
results with localisation and quantification of the compound. Indeed this multi-imaging platform 
allows for the study of compound distribution and quantification in each histological structure like 
the hair follicle and the sebaceous gland. It is thus possible to determine the penetration pathway, 
the compound concentration in each histological region and the target engagement directly within 
the tissue without any labelling (radioactivity or fluorescence).    
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Screening for PsA in Primary Care Psoriasis Patients with Musculoskeletal Complaints with 
PEST, PASE & EARP
MC Karreman,1 A Weel,2 M van der Ven,1 M Vis,1 I Tchetverikov,3 M Wakkee,4 
T Nijsten,4 J Hazes1 and J Luime1 1 Rheumatology, Erasmus University Hospital, Rotterdam, 
Netherlands, 2 Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, 3 Rheumatology, 
Albert Schweitzer Hospital, Dordrecht, Netherlands and 4 Dermatology, Erasmus University 
Hospital, Rotterdam, Netherlands
The purpose of this study was to evaluate the screening performance of the PEST, PASE and EARP 
to identify psoriatic arthritis among primary care psoriasis patients with recurrent spells of musculo-
skeletal complaints (MSC). We conducted a cross-sectional study and patients were selected by ICPC 
code S91 for psoriasis. The presence of recurrent spells of MSC (joints, enthesis or low back pain) 
was determined by telephone interview. Patients completed the PEST, PASE & EARP questionnaires 
before clinical evaluation by a trained research nurse. Assessments included PASI, LEI/MASES, 
66/68-joint count and the presence of nail-psoriasis. When patients reported a painful enthesis on 
LEI/MASES, an ultrasound of the entheses was performed. A PsA case fulfilled the CASPAR criteria. 
Sensitivity and specificity were determined for the PEST and EARP cut off ≥3 and PASE cut off ≥44 
as well as ≥47. In total, 473 psoriasis patients participated (mean age 55.7 (SD 13.9) years, 50.9% 
male). Median PASI score was 2.3 (IQR 1-4) and 71 patients (15.0%) had nail abnormalities related 
to psoriasis. We found 17 new cases of PsA (3.6%) as diagnosed by a rheumatologist. Moreover, 
we found 36 cases of enthesitis, confirmed by ultrasound. The majority of these refrained from 
further evaluation by a rheumatologist, however most of them would classify as PsA according to 
the CASPAR criteria. The EARP had a sensitivity of 87% and a specificity of 33%, for the PEST this 
was 68% and 71%. The PASE had a sensitivity of 66% and a specificity of 55% at the cut off of ≥44 
and 59% and 64% at the cut off of≥47. In conclusion, modest sensitivity was observed for the PEST 
and PASE with an acceptable specificity for the PEST, while the EARP had high sensitivity and low 
specificity, which is undesirable for screening. The performance of all screening tools was lower 
than previously reported in secondary care.    
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Prevalence of Musculoskeletal Complaints and Psoriatic Arthritis in Primary Care Patients 
with Psoriasis
MC Karreman,1 A Weel,2 M van der Ven,1 M Vis,1 I Tchetverikov,3 T Nijsten,4 M Wakkee,4 
J Hazes1 and J Luime1 1 Rheumatology, Erasmus University Hospital, Rotterdam, Netherlands, 
2 Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, 3 Rheumatology, Albert 
Schweitzer Hospital, Dordrecht, Netherlands and 4 Dermatology, Erasmus University 
Hospital, Rotterdam, Netherlands
The purpose of this study was to estimate the prevalence of MSC and PsA in primary care patients 
with psoriasis. In order to do so, we conducted a cross-sectional study in adult primary care 
patients with psoriasis. Patients were identified from GP records by ICPC code S91 for psoriasis. 
Responding patients reporting pain in joints, entheses or the lower back were checked on eligibility 
by a telephone interview and invited for clinical evaluation. Ultrasonoghraphy (US) of the enthesis 
was performed if a patient had at least one tender enthesis (LEI/MASES) by an independent trained 
examiner. Patients were referred to a rheumatologist if clinical evaluation suggested the presence 
of arthritis or axial disease or ultrasonography of the enthesis showed positive Power Doppler(PD) 
signal. A PsA case was defined by opinion of the rheumatologist or fulfilling the CASPAR criteria 
with PD signal in an enthesis on US. In total, 2564 psoriasis patients from 97 GPs were invited. Of 
the 1673 responders (65.2%), 841 (50.3%) were willing to participate. 823 (32.1%) patients reported 
suffering from MSC of which eventually 524 were eligible and clinically evaluated. We identified 
81 cases of PsA, of which 17 (21%) were newly diagnosed, leading to a prevalence of 3.2% (95%CI 
2.5%-3.9%) among primary care psoriasis patients, assuming no additional cases of PsA among 
the non-responders. Besides these cases, we also identified 36 patients with enthesitis confirmed 
by ultrasound, which would increase the prevalence of PsA towards 4.6% (95% CI 3.8%-5.4%). In 
conclusion, the prevalence of PsA among primary care psoriasis patients is estimated to be 3.2%, 
which would increase towards 4.6% if you take the enthesitis cases into account. Moreover, 21% 
of the cases was newly diagnosed. The prevalence of MSC is estimated to be 32.1%, which is 
comparable with the prevalence in general population.    
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The dermal matrix architecture of the skin impacts perceived age and the overall appearance 
of the skin
C Pollefliet,1 K Van Rillaer,1 H Corstjens,1 J Dela Cruz,2 C Fthenakis2 and L Declercq1 1 
BSR Europe, Estée Lauder Companies, Oevel, Belgium and 2 BSR, Estée Lauder Companies, 
Melville, NY
Skin aging is a complex biological process caused by genetic and extrinsic factors e.g. sun exposure, 
smoke, and pollution. Typical clinical signs of skin aging are lines, wrinkles, age spots, and thinning 
of the skin, but also an overall decline in skin radiance is associated with aged skin. At the biological 
level, aging affects all layers of the skin. In the dermal compartment there is an imbalance between 
the synthesis and degradation of the components of the extracellular matrix. In addition the features 
of the dermal matrix are modified and characterized by increased fragmentation of dermal fibers. In 
a clinical study we wanted to quantify these dermal features as a function of age and link these to the 
overall skin appearance. In total the architecture of the dermal matrix of the cheek of 252 Caucasian 
volunteers was evaluated by Reflectance Confocal Microsopy. Analysis of the images recorded at 
the dermal level, showed the presence of mainly thin reticulated fibers in the younger age groups 
while in the elderly there was a shift towards coarse fibers. By means of image analysis, the level of 
dermal fragmentation was quantified and an increase in dermal fragmentation with biological age 
(R=0.51; p<10-4) was measured. Determination of the perceived age of the volunteers by a naïve 
panel showed that people with a high dermal fragmentation index were perceived to look older 
(p=0.04). Furthermore, it was shown by evaluation of the facial Visia-CR images that panelists with 
a high dermal fragmentation had a less radiant skin. It can be concluded that the architecture of 
the dermal matrix has an impact on how the skin is visually perceived. Dermal matrix architecture 
with high fragmented collagen and elastin bundles makes the skin look older and less radiant.   
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Elevated soluble cardiovascular risk markers in psoriasis and atopic dermatitis and evaluation 
of soluble ST-2 as a biomarker in psoriasis
KF Hjuler,1 A Langkilde,1 C Vestergaard,1 M Böttcher,2 M Deleuran,1 L Iversen1 and 
K Kragballe1 1 Dept. of Dermatology, Aarhus University Hospital, Aarhus, Denmark and 2 
Dept. of Int. Medicine, Hospital Unit West, Herning, Denmark
The purpose of this study was to investigate the level of the soluble cardiovascular risk markers 
c-reactive protein (CRP) and homocysteine (Hcy), and sex hormone-binding globulin (SHBG) as 
a risk marker of type-2 diabetes in psoriasis and atopic dermatits. Further, we aimed to study the 
IL-33/ST-2 axis in psoriasis and evaluate whether soluble ST-2 (sST2) could be a biomarker in 
psoriasis. We consecutively enrolled patients with psoriasis (n=55, PASI: 13.8 (mean), age: 49.0 
(mean), male gender: 67 %), AD (n=36, BSA: 29 % (mean), age: 46.9 (mean), male gender: 78 %) 
and controls (n=25, age: 45.0 (mean), male gender: 56 %). A subgroup of patients with psoriasis 
(n=13) were evaluated during anti-TNF treatment and additional blood tests were performed at 3 
and 12 months of treatment. We found higher values of CRP in psoriasis and AD compared with 
controls (Psoriasis: 3.2 mg/L AD: 2.3 mg/L vs. controls: 1.1 mg/L, P=0.002 and P=0.09, respec-
tively). Hcy was 13.5 mmol/L in psoriasis and 12.6 mmol/L in AD vs. 10.3 mmol/L in controls 
(P=0.02 and P=0.09, respectively). SHBG was lower in psoriasis and AD, however insignificantly. 
In the subgroup of psoriasis patients (n=13) treated with anti-TNF agents, a reduction in CRP was 
seen at 3 months (4.2 mg/L vs. 1.7 mg/L, P=0.02) and CRP remained low at 12 months (2.2 mg/L, 
P=0.06). We found significantly lower levels of sST2 in psoriasis compared to controls (76.4 pg/mL 
vs. 130.8 pg/mL, P=0.0008). During treatment a tendency to increasing levels of sST2 was seen, 
however insignificantly. There was no significant difference in levels of IL-33 between psoriasis and 
controls and no significant reduction in IL-33 was seen during treatment. In conclusion, we found 
elevated biomarkers of cardiovascular risk in psoriasis and AD compared to controls, however not 
statistically significant in AD. The IL-33/ST-2 axis may be regulated in psoriasis, but the exact role 
of the cytokines needs to be investigated further.    
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Effects of P-3074, a topical solution of finasteride in the treatment of androgenetic alopecia
M Caserini, F Scarci and R Palmieri Scientific Department, Polichem SA, Lugano-Pazzallo, 
Switzerland
Androgenetic alopecia (AGA) is an inherited androgen-dependent condition causing hair loss in 
men. AGA is determined by an increased rate of conversion of testosterone into dihydrotestosterone 
(DHT) in the scalp. Oral finasteride (FNS) is an effective drug for the treatment of AGA but its use is 
occasionally associated with sexual dysfunctions, due to the systemic inhibition of DHT. A topical 
formulation of FNS (P-3074), vehicled in Hydroxypropyl Chitosan (HPCH) technology, able to act 
on scalp skin follicular portion promoting a cutaneous depot of FNS in the region of hair bulbs, has 
been developed. A dose-finding program was designed to evaluate the PD effect of P-3074 (DHT 
inhibition at scalp and plasma levels). Six active doses of P-3074, set in 6 different volumes (i.e. 
100 μL, 200 μL, 300 μL 400 μL o.d., 1 mL o.d. and 1 mL b.i.d.), were applied to subjects’ scalp (6 
per group), in comparison to vehicle and 1 mg oral FNS. All the treatments were administered for 
7 days; punch scalp biopsies were collected at baseline and at the end of treatment. Changes from 
baseline in DHT scalp/serum levels were calculated and presented as percentage of inhibition. After 
a multiple treatment for one week, percentage of inhibition of scalp DHT was similar across all 
formulations, with values ranging from -37% to -64%. On the other hand, serum DHT was reduced 
by -24.4 and -26.2% with 100 and 200 μL P-3074, respectively. The changes in the other treatment 
groups ranged from -38 to -80%, while for the vehicle was -7.1%. The comparison between lower 
doses and other doses was statistically significant. No differences were detected between 100 and 
200 μL. After 1 week of treatment with the six topical doses of P-3074, plasma FNS was below the 
lower quantification limit. FNS plasma exposure was significantly lower with the topical than the 
oral product. At doses up to 200 μL, topically applied P-3074, allowed a significant and consistent 
decrease of scalp DHT (comparable to oral FNS) and only marginally in serum DHT, potentially 
minimizing the untoward side effects linked to a systemic DHT reduction    
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Assessment of symptom measurement instruments for atopic dermatitis: a systematic review
LA Gerbens,1 CA Prinsen,2 C Apfelbacher,4 J Chalmers,3 A Drucker,5 L Kobyletzki,6 
H Nankervis,3 A Svensson,6 J Zhang7 and PI Spuls1 1 Dermatology, University of Amsterdam, 
Amsterdam, Netherlands, 2 Epidemiology and Biostatistics, VU University Medical Center, 
Amsterdam, Netherlands, 3 Centre of Evidence Based Dermatology, University of Nottingham, 
Nottingham, United Kingdom, 4 Epidemiology and Preventive Medicine, Medical Sociology, 
University of Regensburg, Regensburg, Germany, 5 Dermatology, University of Toronto, 
Toronto, ON, Canada, 6 Dermatology, Institution for Clinical Science, Lund University, 
Malmö, Sweden and 7 Dermatology, Peking University People’s Hospital, Peking, China
Symptoms are a core outcome domain for atopic dermatitis (AD). Various measurement instruments 
exist to measure symptoms however they vary in quality and there is a lack of standardization in 
trials. Our aim was to systematically assess the evidence on measurement properties of AD symptom 
measurement instruments and to inform the Harmonising Outcome Measures for Eczema (HOME) 
Initiative for an international consensus process. MEDLINE and EMBASE (until August 27th 2014) 
were searched for development or validation studies. Assessment of the quality of the measurement 
properties, methodological study quality and recommendations were based on predefined criteria 
and by using the COnsensus-based Standards for the selection of health Measurement INstruments 
(COSMIN) checklist. Our search identified a total 2153 articles, 26 met inclusion criteria. Fourteen 
instruments were reviewed. The Itch Severity Scale (ISS), Patient-Oriented Eczema Measure (POEM) 
and Self-Assessed Eczema Area and Severity Index (SA-EASI) had positive overall quality ratings 
and could be recommended depending on results of further validation studies. ISS and POEM had 
been validated for most of the measurement properties, SA-EASI only for 2. ISS had conflicting 
rating for reliability and indeterminate rating for responsiveness. POEM had indeterminate rating 
for reliability and measurement error. The remaining 11 instruments had negative overall quality 
ratings or had almost not been validated. The ISS and POEM are currently the best instruments to 
assess symptoms of AD.    
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Defining severity cut offs and minimal clinically important differences of the Epidermolysis 
Bullosa Disease Activity and Scarring Index (EBDASI)
SV Jain,1 AG Harris,1 JS Su,2 D Orchard,2 LJ Warren,3 H McManus4 and DF Murrell1 1 
Dermatology, St George Hospital, UNSW, Sydney, NSW, Australia, 2 Dermatology, Royal 
Children’s Hospital, Melbourne, VIC, Australia, 3 Dermatology, Women’s and Children’s 
Hospital, Adelaide, SA, Australia and 4 Biostatistics, Kirby Institute, UNSW, Sydney, NSW, 
Australia
The EB Disease Activity and Scarring Index (EBDASI) was developed to measure disease activity and 
damage separately to make a combined total severity score for clinical trials. The initial validation 
compared EBDASI with the Birmingham EB score and the physician global assessment in 15 EB 
patients with 5 assessors, finding the EBDASI had higher inter-rater and intra-rater reliability.1 The 
aim of this further and larger multicentre study was to assess the responsiveness of the EBDASI by 
characterising disease severity and the clinical response of epidermolysis bullosa over time. 48 EB 
patients were evaluated using the EBDASI, a physician assessment of disease severity (mild, mod-
erate, severe) and a physician assessment of change compared to the previous visit. Site-specific 
analysis determined EBDASI score ranges for patients in each severity category and correlated 
scores with an EB-specific quality-of-life measure. The minimal clinically important difference 
of the EBDASI activity score was calculated in the responsiveness analysis. Receiver operating 
characteristic (ROC) curves were used in all analyses to determine EBDASI score cut-offs. EBDASI 
total score ranges for mild, moderate and severe disease were found to be 0-42, 43-104 and 
>104, respectively, and correlated with quality-of-life measures. The minimal clinically important 
differences of the EBDASI was a reduction of greater than 9 in the activity score for improvement, 
and an increase in EBDASI activity score of greater than 3 for deterioration. All cut-offs correctly 
classified over 75% of patients. These findings confirm the responsiveness of the EBDASI to change 
in patients’ clinical status over time. The EBDASI may be useful in defining and charting the disease 
severity in EB in clinical trials.    
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Sensitivity and Drug Tolerance of Anti-Drug Antibody Screening Assays for Ixekizumab
T Muram,1 B Nickoloff,1 A Blauvelt,2 K Papp,3 K Gordon,4 I Stoykov,1 M Vincent1 and 
R Konrad1 1 Lilly, Indianapolis, IN, 2 Ore Med Res Ctr, Portland, OR, 3 Probity Med. Res, 
Toronto, ON, Canada and 4 Northwestern U., Chicago, IL
The use of protein based medications, including monoclonal antibodies, presents the possibility of 
the induction of anti-drug antibodies (ADA). Differences in ADA assay methods and results have 
added to confusion as to their clinical significance. Currently, ixekizumab, an anti-interleukin 
17A monoclonal antibody, is being studied for the treatment of psoriasis. In order to understand 
the possible development of antibodies to this drug, we have used two distinct methodologies 
for measuring antibody production: an affinity capture elution (ACE) ADA screening assay and a 
MesoScale Discovery (MSD) bridging format. These assays each demonstrated sensitivity of better 
than 10 ng/mL; however, a significant difference with regard to assay performance in the presence 
of ixekizumab (i.e., drug tolerance) was observed between the two methods when compared using 
500 ng/mL ADA. The MSD bridging assay demonstrated drug tolerance of approximately 10 μg/mL, 
while the ACE assay format exhibited drug tolerance of approximately 230 μg/mL, more than 20-fold 
greater than the MSD format. Thus, ACE assay for measuring ADA, in the presence of ixekizumab, 
was markedly superior to the MSD bridging format. Importantly, the ACE assay allows for optimal 
detection of true positives when drug is present in serum and therefore reduces the need for a 
lengthy treatment washout period to detect ADA. This study illustrates how the selection of assay 
format may greatly affect ADA detection results in patients treated with monoclonal antibodies.   
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Examining the prevalence of Alcohol Use Disorders (AUD) in patients with skin disease, a 
cross-sectional study
K Aljefri,1 C Muirhead,2 D Newbury-Birch,3 E Kaner,2 E Gilvarry,2 V Araujo-Soares,2 
NJ Reynolds2 and P Hampton1 1 Dermatology, Newcastle NHS Trust, Newcastle upon Tyne, 
United Kingdom, 2 Newcastle University, Newcastle upon Tyne, United Kingdom and 3 
Teeside University, Middlesbrough, United Kingdom
Although an association between excessive alcohol consumption and psoriasis has been identified, 
such a link is not established in other chronic inflammatory skin conditions. We examined the 
prevalence of alcohol use disorders (AUD) using the validated Alcohol Use Disorders Identification 
Test (AUDIT) in patients with different skin diseases. In this observational questionnaire single centre 
study, 609 patients were recruited in four inflammatory groups (psoriasis, eczema, lupus and other) 
and a reference group with non-inflammatory skin conditions. We used three validated screening 
tools: the alcohol use disorders identification test (AUDIT), hospital anxiety and depression score 
(HADS) and dermatology life quality index (DLQI). An AUDIT score of 8 defined an alcohol use 
disorder. 22.7% of our population had AUD. AUD were more prevalent in males and those with 
later date of birth. Patients with inflammatory skin conditions had a higher prevalence of AUD than 
the reference group, 24.5% vs. 14.3% respectively. In the primary analysis, the odds ratio(OR), 
(with 95% CI) for AUD among psoriasis patients relative to the control group was 2.69(1.49-4.69) 
and adjusting for gender and age 1.65(0.86-3.17). Exploratory analyses showed the OR for AUD in 
eczema patients relative to the reference group was 3.00(1.69-5.33) and adjusting for gender and 
age 2.00(1.03-3.85). The mean DLQI score was 10.29 (SD 7.57) in the eczema group and 7.71 (SD 
6.73) in the psoriasis group. Our data support the previously known problem of AUD in patients 
with psoriasis using a validated measure, the AUDIT. For the first time we have shown that AUD 
are more prevalent in eczema patients comparing to a reference population. Despite controlling 
for age and gender the possibility of other confounders cannot be entirely excluded and further 
investigation is needed in larger populations in non-hospital settings to confirm these findings.   
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Cessation of Spread as a Motivation for Treatment in Vitiligo
N van Geel, V De Smedt, B Boone, H Lapeere, S De Schepper, C Naeyaert, L De Smet, 
J Vandeweghe and R Speeckaert Dermatology, Ghent University Hospital, Gent, Belgium
Vitiligo is a chronic depigmentary skin disorder with an important impact on quality of life. Outcome 
measures in clinical trials most often focus on repigmentation, however cessation of spread can 
also be an important outcome measure. The aim of this study is to improve our understanding of a 
worthwhile treatment outcome from a patient perspective. In this study we investigated the motiva-
tion for treatment and perception of disease impact in 799 vitiligo (non-segmental) patients. Patients 
were asked to score their current perception about treatment motivation as well as the impact of 
the disease. The motivation for treatment was high (score of ≥ 7/10 in 87.4%), and decreased only 
slightly if disease stabilisation was proposed as a treatment goal (score of ≥ 7/10 in 83.5%). Less 
than 10% of patients would not be willing to treat (motivation score < 4/10) in the latter setting. 
Patients were most motivated to treat visible areas such as the face and the hands. There was a 
negative correlation between a higher affected body surface area and the motivation to treat if 
stabilisation would be the outcome (p=0.002). There was a wide variety of reported disease impact 
scores which reflects the individual difference in coping with this disease. Higher impact scores 
were associated with a more extensive affected body surface area. The reported disease impact was 
higher in women and increased throughout life until the age of 50. In men, the impact remained 
stable from the age of 20 and declined after the age of 60. In conclusion, this study highlights the 
important role of disease stabilisation as a therapy goal which could be included as an outcome 
measure in clinical trials. The continuous high impact of the disease during life stresses the need 
to regard vitiligo as a chronic disorder where the patients’ desire for treatment persists. The results 
of this study can be used to improve the individual approach of our patients adequately and to 
propose the most applicable treatment options.    
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Analysis of Infections with Ixekizumab in 7 Clinical Studies of Psoriasis
K Papp,1 K Winthrop,2 D Braun,3 N Acharya,3 A Beselin3 and H Bachelez4 1 Probity 
Med. Res, Waterloo, ON, Canada, 2 Oregon Health and Science U, Portland, OR, 3 Lilly, 
Indianapolis, IN and 4 Service de Dermatologie, Hôpital Saint Louis, Paris, France
We evaluated the incidence of infections in patients with psoriasis treated with ixekizumab (IXE), 
an anti-IL-17A IgG4 monoclonal antibody with high binding affinity, relative to etanercept (ETN) or 
placebo (PBO). Data were integrated from the induction period of 3 phase 3 randomized, controlled 
trials (RCT; 0-12 weeks [wks]), the maintenance period of 2 of the 3 RCTs with a randomized with-
drawal design (12-60 wks), and all patients exposed to IXE from 7 psoriasis trials ( N=4204;4730 
patient years [PY] of exposure;doses ranging from 5 mg – 150 mg). During the induction period 
patients received IXE every 2 (IXE Q2W; N=1167) or 4 wks (IXE Q4W; N=1161) following a 160-mg 
starting dose, ETN (50 mg biweekly; N=739), or PBO (N=791). The maintenance period included 
patients re-randomized to IXE Q4W (N=416), IXE Q12W (N=408), or PBO (N=402). At 12 wks, 
27% in IXE Q2W and Q4W groups (total IXE) developed infections vs 22% in ETN or 23% in PBO 
groups. These differences were statistically significant (p<0.05) and mostly driven by events mild in 
severity (17%, total IXE) with no differences in severe infections (<1% each group). The proportion 
with serious infections was comparable across treatments (total IXE: 0.6%, ETN: 0.4%, PBO: 0.4%). 
Following re-randomization, exposure-adjusted infection rates decreased over time with IXE (Wk 
12 vs. 60: 118/100 PY vs. 72/100 PY). The exposure-adjusted infection rates across all 7 studies 
was 47/100 PY. In the first 12 wks, the proportion with candidiasis was 1.4% in IXE Q2W, 0.6% in 
IXE Q4W, 0.7% in ETN, and 0.5% in PBO; nearly half were cases of oral candidiasis (which was 
dose-dependent). Exposure-adjusted candidiasis rates were 4.3, 3.7, and 2.7 per 100 PY for the first 
12 wks, re-randomized period, and across all studies, respectively. All cases were non-serious. None 
led to discontinuation. While infections were more frequent with IXE than ETN and PBO, most were 
mild to moderate. Exposure-adjusted infection rates decreased over time.    
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Topical application of vitamin D3 analogue and corticosteroid to psoriasis plaques synergis-
tically depresses expansion of Th17 cells in the lesional skin
T Fujiyama, T Ito, K Tatsuno and Y Tokura Dermatology, Hamamatsu University School of 
Medicine, Hamamatsu, Japan
Topical combined therapy with vitamin D3 analogue calcipotriol and corticosteroid betamethasone 
dipropionate is widely used for the treatment of psoriasis. Despite its clear clinical effectiveness, the 
underlying mechanism remains unclear. Since Th17 cells are deeply involved in the pathogenesis 
of psoriasis, we investigated the effect of the topical combined applicant, focusing on the skin-infil-
trating Th17 cells. In five patients with psoriasis vulgaris, calcipotriol ointment (Cal), betamethasone 
dipropionate ointment (Bet), or two-compound formulation (CB; Dovobet ®) was applied to three 
different sites with similar severity of psoriatic plaque once a day for 14 days. One non-applied 
lesion was employed as control (Cntrl). Four-mm biopsy specimens were taken from the four sites 
and were cut into two pieces. One was used for HE staining and for immunohistochemical staining 
for CD4, CD8, and IL-17. The other half specimens are used for in vitro expansion of skin-infiltrat-
ing T cells with anti-CD3/CD28 antibodies and IL-2 by using our established method. Cells were 
examined in their phenotype and intracellular cytokine pattern to identify Th17, Th22, Th1, and 
Th2 cells. Clinical improvement was found in the order of CB>Cal>Bet>Cntrl or CB>Bet>Cal> Cntrl. 
Consistently, the histological changes of psoriasis were normalized in the same order. While CD4/
CD8 ratio in the T cell infiltrate was not significantly different among the four groups, the number 
of IL-17+ cells in the skin tissue was as follows: CB<Cal< Bet<Cntrl. Furthermore, T cells expanded 
via TCR stimulation from the lesional skin contained the following number of IL-17+CD4+ T cells: 
CB, 3.5 ± 3.1; Cal, 8.2 ± 6.0; Bet, 13.5 ± 5.6; and Cntrl, 36.7± 22.7 (×105). IFN-γ+ CD4+ T cells 
were: CB, 35 ± 6.7; Cal, 127.9 ± 32.1; Bet, 122.3 ± 17.8; and Cntrl, 190.4± 37.7 (×105). Thus, the 
topical combined therapy efficaciously depressed skin-infiltrating Th17 cells as well as the other T 
cell populations, and the expansion of Th17 cells was also suppressed. These findings support its 
clinical effectiveness for psoriasis.    
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A systematic review & meta-analysis on biomarkers for disease severity in atopic dermatitis
JL Thijs,1 T Krastev,1 S Weidinger,2 CF Buckens,3 M de Bruin-Weller,1 CA Bruijnzeel-
Koomen,1 C Flohr4 and D Hijnen1 1 Dermatology, UMC Utrecht, Utrecht, Netherlands, 2 
Dermatology, Venereology and Allergy, University Hospital Schleswig-Holstein, Campus Kiel, 
Germany, 3 Radiology, UMC Utrecht, Utrecht, Netherlands and 4 Paediatric Dermatology, St 
John’s Institute of Dermatology, Guy’s and St Thomas’ Hospitals NHS Foundation Trust and 
King’s College, London, United Kingdom
A large number of studies investigating the correlation between severity of AD and various bio-
markers have been published. However, a systematic review on this subject had not yet been 
performed. The aim of this review was to identify, evaluate and synthesize the evidence examining 
the correlation of biomarkers with disease severity in AD patients. Three electronic databases were 
systematically searched. Meta-analysis was carried out for biomarkers with a reported R-value in at 
least four studies. To avoid selection bias, we additionally pooled the patients from all studies and 
classified them based on the conclusions of the individual studies. A total of 224 papers, reporting 
115 different biomarkers were critically appraised. Studies were divided into groups. The first group 
comprised of RCT’s and cohort studies (longitudinal studies) which reported multiple measurements 
over time. Studies that reported only one measurement per patient (cross-sectional studies) included 
patient cohorts and case series.A total of 108 papers reported sufficient data for meta-analysis. Four 
biomarkers from the longitudinal group and nine from the cross-sectional group were eligible for 
meta-analysis. Pooling all longitudinal studies resulted in data from 5328 patients (173 publications). 
Data from 15471 patients was pooled in the cross-sectional group (148 publications). Serum TARC 
is the most reliable biomarker currently available. Serum TARC levels have been determined in 
relatively large numbers of patients from different studies, showing pooled r-values of 0.60 and 
0.70 in longitudinal and cross-sectional studies, respectively. Additional biomarkers that could 
prove useful but require additional research include serum CTACK, serum MDC, serum LDH, 
serum sE-selectin and serum IL-18.    
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Intralesional Bleomycin Injections for Cutaneous and Soft Tissue Vascular Malformations
SE Horbach,1 I Rigter,2 JH Sillevis Smitt,3 J Reekers,4 PI Spuls3 and CM van der Horst1 1 Plastic 
and reconstructive surgery, Academic Medical Center, Amsterdam, Netherlands, 2 Hospital 
Pharmacy, Academic Medical Center, Amsterdam, Netherlands, 3 Dermatology, Academic 
Medical Center, Amsterdam, Netherlands and 4 Interventional Radiology, Academic Medical 
Center, Amsterdam, Netherlands
Vascular malformations are congenital anomalies of lymphatic, venous, arteriovenous or capillary 
origin. For lesions involving skin and soft tissue, intralesional injections with the cytotoxic and 
sclerosing agent bleomycin are increasingly used. However, pulmonary fibrosis could potentially 
be a severe complication, known from systemic bleomycin therapy for malignancies. Our objective 
was to investigate the effectiveness and safety of intralesional bleomycin injections for vascular 
malformations, when possible relative to other sclerosants. A PubMed, EMBASE, CENTRAL and 
grey literature search for original studies (1995-now), reporting outcome of intralesional bleomycin 
in patients with vascular malformations (n≥10). Predefined outcome measures of interest were size 
reduction, symptom relief, Quality of Life, adverse events (including pulmonary fibrosis) and patient 
satisfaction. 27 studies enrolling 1325 patients were included, 4 were eligible for meta-analysis. 
Quality of evidence was generally low. Good to excellent size reduction was reported in 84% of lym-
phatic and 87% of venous malformations. Only minor adverse events were reported. Meta-analysis 
of venous malformations treated with bleomycin versus other sclerosants, showed similar size reduc-
tion (OR 0.67 CI [0.24, 1.88]), but a significant lower adverse event rate (OR 0.1 [CI 0.03, 0.39]) 
and less severe complications after bleomycin. Symptom relief, QoL and patient satisfaction were 
inadequately reported. Data for arteriovenous and capillary malformations were scarce.Intralesional 
bleomycin injections seem effective in reducing the size of lymphatic and venous malformations, 
and may lead to less (severe) adverse events than other sclerosants. The included literature does not 
provide evidence that pulmonary fibrosis is a complication of intralesional bleomycin injections.   
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Safety and Efficacy of Isotretinoin for Acne Vulgaris: a retrospective study 
S Rajpara,1 A Rahman,2 S Tabassum,3 M Islam4 and J Moran1 1 Dermatology, Aberdeen Royal 
Infirmary, Aberdeen, United Kingdom, 2 Dermatology, CMH lahore medical college, Lahore, 
Pakistan, 3 Dermatology, Aga Khan University Hospitals, Karachi, Pakistan and 4 Community 
health sciences, Aga Khan University Hospitals, Karachi, Pakistan
The response rate, longevity and side effects depend on the severity of acne and total dose/duration 
of treatment, however there is no consensus. This cohort study looked at the cumulative dose/ 
response and side effects in patients treated between 2010- 2012. Duration and severity of acne 
(global acne grading system GAGS), total dose/duration of isotretinoin, clinical response and side 
effects data was collected. Depression was assessed by HANDS (Harvard National Depression 
Screening Day Scale). 4 patient groups based on cumulative dose were: Group I <80mg/kg, II 80 – 
119 mg/kg, III 120 – 149 mg/kg, IV >150 mg/kg. Data was analyzed with SPSS 17. 207/400 were 
women and 193/400 men, mean age 22.3 +7.2 years. 11/400(2.8%) were on antidepressants and 
29/400 (7.3%) had h/o depression. The GAGS was recorded as mild in 25/230, moderate 150/230, 
severe 55/230. The mean treatment was 6.32 + 1.75 months. Out of 349/400 completed the course, 
347/400 had excellent and 2/400 partial response. 40/400 lost to follow up and 11/400 stopped 
treatment due to side effects. 27 were in group I, 158 in group II, 127 in group III and 37 in group 
IV for the cumulative dose received. Mean dose of isotretinoin was 117.31+28.64 /kg body weight 
with no significant difference between the groups for the response. Side effects: dryness of skin and 
lips (387 & 381). Musculoskeletal 69 (17.3%), nose bleeds 46(11.5%), mood changes 36 (9%), 
headache 21(5.3%), lipid changes 9 (2.3%), photosensitivity 7 (1.8%) and liver enzyme changes 5 
(1.3%). The reasons for discontinuing: worsening of depression (4/11), musculoskeletal side effects 
(3/11), 1 each due to nose bleed, arthralgia,uveitis and cheilitis. 5/11 on antidepressants improved 
during treatment, 3 got worse and 3 lost to follow up. Total dose between 80 to 149 mg/kg gives 
excellent response in most patients irrespective of acne severity. Effects on pre existing depression 
are unpredictable.    
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Bath-PUVA therapy increases circulating activated regulatory T cells in patients with psoriasis
R Kubo,1 S Muramatsu,1 Y Sagawa,1 C Saito,1 S Kasuya,1 A Nishioka,1 E Nishida,1 S Yamazaki2 
and A Morita1 1 Department of Geriatric and Environmental Dermatology, Nagoya City 
University Graduate School of Medical Sciences, Nagoya, Japan and 2 Department of 
Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
Bath-PUVA therapy is applied for the treatment of psoriasis due to its efficacy, safety profile, and 
low cost. The pathogenesis of psoriasis might be an imbalance of Th17 cells and regulatory T cells 
(Treg). We previously evaluated the effects of bath-PUVA therapy on Th17/Treg balance in peripheral 
blood obtained from patients with psoriasis. Bath-PUVA therapy significantly reduces the number 
of Th17 cells. The Treg Functional Ratio (%), defined as %suppression of responder cell prolifer-
ation by Treg, is significantly lower in patients (72.1±24.8% n=15) than in controls (94.4±4.3% 
n=9, p=0.015). The Treg Functional Ratio is significantly increased, and Treg function is restored 
to almost normal levels. The Treg Functional Ratio is inversely correlated with the Psoriasis Area 
and Severity Index score (r= -0.407 p=0.084). These findings confirm that Treg are dysfunctional 
in psoriasis patients, and that bath-PUVA therapy restores Treg function in most patients. In the 
present study, we examined three distinct Treg subsets: activated Treg (aTreg), resting Treg (rTreg), 
and cytokine-secreting non-suppressive Treg (non-Treg). aTreg is considered to have the strongest 
suppressive activity among the three subsets. We examined these subsets from the peripheral blood 
before and at each of the 5 sessions of bath-PUVA therapy in 10 psoriasis patients. aTreg levels were 
significantly increased in the early sessions of bath-PUVA therapy and later diminished afterward. 
The psoriasis lesions improved concomitantly with the increase in aTreg. The improvement was 
negatively correlated with the Psoriasis Area and Severity Score. Bath-PUVA therapy resolves the 
Th17 and Treg imbalance in patients with psoriasis and induces aTreg.    
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Quality of life measurement in therapeutic trials of psoriasis: a systematic review
FM Ali,1 A Cueva,3 J Vyas,1 V Piguet,1 S Salek2 and AY Finlay1 1 Cardiff University, 
Cardiff, United Kingdom, 2 University of Hertfordshire, Hatfield & Institute for Medicines 
Development, Cardiff, United Kingdom and 3 Senescyt and Centro De La Piel, Quito, 
Ecuador
The aim of this systematic review [SR] was to find out which studies have used quality of life [QoL] 
measures to assess the impact of treatments for psoriasis. The review methodology followed PRISMA 
guidelines. All available articles describing randomized controlled trials of therapies for psoriasis 
that included QoL measurements published up to November 2014 were identified. Six databases 
were examined with 388 search terms, and grey literature was identified. Abstracts of articles were 
reviewed independently by two assessors and included if they met the specified criteria. A third 
adjudicator resolved any differences of opinion. Two authors independently reviewed risk of bias 
with the JADAD scale and extracted data using the Cochrane Handbook for SR form. Of 3597 
screened article abstracts, 329 articles were selected for detailed review, 100 trials met the eligibility 
criteria, describing research on a total of 33,215 patients. Of the 100 trials that measured QoL, 
33 tested topical therapy, 18 systemic therapy, 39 biologics, 9 phototherapy, and 10 tested other 
interventions. The most commonly investigated interventions for psoriasis were topical calcipotriol 
(13 trials), topical betamethasone (7), methotrexate (7), ciclosporin (3), etanercept (14), ustekinumab 
(8) and phototherapy (9). The Dermatology Life Quality Index [DLQI] was the most commonly used 
QoL tool (number of studies=83, 83%), followed by the Short Form 36 [SF-36] (31, 31%), EuroQol 
[EQ-5D] (15, 15%), Psoriasis Disability Index [PDI] (14, 14%) and Skindex (5, 5%). The number 
of reports of psoriasis interventions that included QoL measurement has gradually increased over 
the years: 1998-2004 = 12, 2005-2009 = 33, and 2010-2014 = 55. Where QoL was measured 
in the assessment of interventions in psoriasis, the DLQI was the most commonly used tool. The 
findings of this study indicate that there is an increasing recognition of the value of QoL assessment 
in monitoring the efficacy of interventions in psoriasis.    
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The WHO Surgical Checklist: Patterns Compliance in an UK Dermatology Regional Referral 
Centre
T Tian, L Myers and D De Berker Bristol Royal Infirmary, Bristol, United Kingdom
The WHO surgical checklist was introduced in 2009 and is associated with reduced morbidity, 
mortality, and improved team work. Its efficacy correlates with compliance, which has been studied 
extensively in surgical speciaties but not in Dermatology. The aim of this study is to 1) establish use 
of the checklist, 2) identify patterns of compliance. Records of patients who had dermatological 
surgery under local anaesthetic at a British regional referral centre were studied between January 
- May 2015. 208 subjects were 111 men and 89 women; the mean age was 58 (range 23 - 93). 
Most patients underwent excision biopsies (73%); 15% had surgery to multiple sites. 83% and 78% 
of checklist items were filled in for the pre-operative and post-operative checklists respectively. 
Full-completion rate for the pre-operative checklist (38%) was almost half of that of the post-op-
erative checklist (64%). However, 16% of post operative checklists were completely unfilled. The 
areas of highest compliance were ‘Allergies’ (89%), ‘Pace Maker’ (92%) and ‘Sharps Count’ (82%). 
The areas of least compliance were ‘Patient Identity’ 73%), ‘Surgical Site’(70%), ‘Pressure Areas’ 
(73%) and ‘Antibiotics’ (67%). Significant differences exist between pre-operative & post-operative 
checklist compliance (p < 0.0001). The pre-operative checklist is much more likely to be partially 
filled, whereas the post-operative checklist is more likely to be unfilled or fully filled (p<0.0001). 
This may relate to logistical barriers in checklist completion. ‘Patient identity’ & ‘surgical site’ had 
the lowest compliance; errors could lead to wrong patient or wrong site surgery especially as a 
sixth of our patients have multiple-site surgery. However patient identity is less likely to be mistaken 
where surgery is under local rather than general anaesthetic. Factors influencing compliance are 
complex and multifactorial. Compliance is known to correlate with safety outcomes, thus further 
work is needed to establish staff attitudes and barriers to compliance to help improve patient safety. 
This work is currently underway in our Dermatology department.    
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Expression of Micro RNA 93 in Early Stage Mycosis Fungoides, Comparative Study
N Nagui,1 L Rashed,1 MI Abd El-latif1 and W Mahmoud2 1 Cairo University, Cairo, Egypt and 
2 al hood almarsoud hospital, Cairo, Egypt
CTCL are non-Hodgkin lymphomas characterized by a dominant skin-homing T-cell clone with 
different clinical presentations. MF is the most common subtype. It includes hypopigmented, hyper-
pigmented, ichthyosiform, pityriasis lichenoides-like, granulomatous, folliculotropic, bullous, pal-
mo-plantar, pagetoid reticulosis and granulomatous slack skin, several gaps are still present in our 
understanding of the pathogenesis. MiRNAs are small noncoding RNA molecules involved in the 
regulation of various physiological and pathological processes. Altered expression of different miR-
NAs has been observed in both solid tumors and haematological malignancies. MiRNA-93, one of 
members of miR-17–92 cluster, which role was proved in enhanced cell survival, promoted sphere 
formation and augmented tumor growth. The aim of this study is to evaluate the expression level of 
miRNA-93 in early stage MF. 15 patients with early stages MF as well as 15 age and sex matched 
healthy controls were included. Clinical examination was done and levels of miRNA 93 in both 
lesional and non lesional biopsies were assessed by PCR. Significant increase in miRNA-93 in both 
lesional and non lesional biopsies of the patients in comparison to controls, with more increase in 
its level in lesional skin than non lesional skin. There was significant positive correlation between 
miRNA-93 levels and age in both lesional and non lesional biopsies. Also there was significant 
positive correlation between miRNA-93 and duration in non lesional skin biopsies only. But there 
was no significant difference in miRNA-93 levels as regards sex of the patients, extent of disease, 
or MF types in both lesional and non-lesional skin biopsies. Our study concluded that miRNA-93 
may be used as a diagnostic tool of MF. Further studies are required to verify the role miRNA-93.   
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Listening to classical music and its effects on saliva stress parameters in psoriasis in-patients.
O Heringa,1 W Owczarek,2 M Kozlowska3 and A Zalewska-Janowska1 1 Psychodermatology, 
Medical University of Lodz, Lodz, Poland, 2 Dermatology, Central Clinical Hospital of 
Military Institute of Medicine, Warsaw, Poland and 3 Dermatology Department, Pediatrics 
Dermatology and Derma Oncology, Medical University of Lodz, Lodz, Poland
The aim of this study was to assess the physiological and psychological effects on stress parameters 
within psoriasis in-patients after listening to classical music. Psoriasis in-patients were given both 
physiological and psychological sets of measurement for a two-day period (day one control, day two 
experiment). Physiological measurement consisted of measuring cortisol and dehydroepiandroster-
on-sulphate (DHEA-S) from saliva samples (using ELISA). A total of 12 saliva samples were collected 
(half with no music and the other half with classical music). These samples were collected at three 
different points in time (morning, afternoon, evening and a 30 minute follow up for each of them). 
This made it possible to compare each saliva measurement between conditions. Psychological 
measurements were taken to measure depression (Beck’s Depression Inventory), quality of life 
(Skindex-29), stress (Rahe & Holmes Stress Inventory) and anxiety (STAI). Saliva measurements show 
several results. Concerning DHEA-S, there is a significant effect between control and experimental 
group (F(1,30)= 25,853; p< 0,001; eta2=0,463) and between different points in time (F(2,58)=3,757; 
p< 0,003; eta2=0,111) DHEA-S levels are higher after 30 minutes of listening to classical music 
in the afternoon (M= 8,38 vs M= 7,94) and evening samples (M= 8,98 vs M= 8,47)). Concerning 
cortisol, a significant effect was found between different points in time (F(2,50)=37,79; p< 0,001; 
eta2=0,557), where cortisol levels decreased during the day (M= 45,55 > M= 38,6 > M= 31,26). 
Beck’s Depression Inventory showed a significant result in post measurement (p= 0,016, SD= 4,32). 
In conclusion, when treating psoriasis patients, listening to classical music might be an additional 
technique to take into account.    
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Natural history of acne lesions and atrophic acne scars within a 6-month study period
A Layton,1 V Bourdes,2 L Petit,2 V Bettoli,3 R Bissonnette,4 B Dreno,5 J Tan,6 V Torres,7 
P Andres2 and P Martel2 1 Harrogate District and Trust, Harrogate, United Kingdom, 2 
Galderma R&D, Sophia Antipolis, France, 3 University of Ferrara, Ferrara, Italy, 4 Innovaderm 
Research, Montreal, QC, Canada, 5 CHU Nantes, Nantes, France, 6 Windsor Clinical 
Research Inc and Western University, Windsor, ON, Canada and 7 Juarez Hospital, Mexico 
City, Mexico
The natural history of acne lesions and the genesis of acne scarring are poorly described. This study 
used a half-face design over 24 weeks of treatment with adapalene/benzoyl peroxide to investigate 
the evolution of primary and secondary acne lesions. Subjects (N=32) with moderate acne (20-40 
inflammatory lesions; ≤1 nodule, and ≥10 atrophic acne scars) were included and evaluated twice 
weekly for 2 months and every 2 weeks for an additional period of 4 months. Natural history of 
lesions (closed comedones, papules, pustules, postinflammatory lesions with/without hyperpigmen-
tation, atrophic acne scars) was tracked by clinical evaluation and standardized digital photography 
on the vehicle side. Descriptive analyses (duration and transition between lesions) and modelling 
of lesion progression was performed using a Bayesian network. A classification method (Kohonen 
maps) was used to define parameters involved in scarring. Primary lesions were transient with a 
mean duration of 5.8±4.1 days for papules, 3.9±1.2 days for pustules and 7.1±5.8 days for closed 
comedones. Scars were continuously forming and 36% of those were transient (resolved within 
the 6-month study period; mean duration of 41±38 days). The vast majority of scars (98%) were 
derived from papules and postinflammatory lesions. Overall, the probability of scar occurrence 
was 5.7%. Duration of papules appeared as a main parameter involved in the risk of scarring. This 
was the first study evaluating the dynamic nature of acne lesions. Scarring occurs continuously 
and derives primarily from papules and postinflammatory lesions. Prevention of scarring relies on 
early treatment of acne lesions.    
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A comparison of atrophic and hypertrophic facial photoageing
J Ayer, RE Watson, T Griffiths and CE Griffiths The Dermatology Centre, Salford Royal NHS 
Foundation Trust & The University of Manchester, Manchester Academic Health Science 
Centre, Manchester, United Kingdom
Photoageing is due to the cumulative effects of sun exposure superimposed on chronological 
cutaneous ageing. Clinically, two main phenotypes of facial photoageing exist: atrophic smooth 
telangiectactic skin (AP) and; hypertrophic wrinkled skin (HP). AP is prone to the development of 
non-melanoma skin cancers (NMSC). The mechanisms that underpin these two disparate phenotypes 
are poorly understood. The aim of this study was to evaluate the histological differences between 
phenotypes by examining: 1) the morphology of epidermis and dermal epidermal junction (DEJ) and; 
2) the composition and distribution of 4 relevant biomarkers [elastic fibres; fibrillin-rich microfibrils 
(FRM); collagen VII and; von Willebrand Factor (vWF)] in the dermal extracellular matrix from sub-
jects with either AP or HP [n=20 per group (mean ± SE); AP (78.7y ±2.02); HP (74.5.6y ±2.08)]. We 
found that AP epidermis was thicker than HP (P< 0.0001) but there were no significant differences 
in DEJ convolution between phenotypes (P>0.05). The percentage of dermis occupied by mature 
elastin fibres was significantly greater in HP than AP (P<0.0001), but the dermis of HP was less 
enriched in FRM than AP (P<0.05). AP was found to be collagen VII-poor compared to HP (P<0.05) 
but, as expected, was more vascular with a greater number of blood vessels (P<0.001 & P< 0.0001, 
respectively). AP had significantly more NMSC (n=25) than HP (n= 0). No differences were found in 
any of these biomarkers in sun-protected buttock skin obtained from the same patients. This study 
demonstrates that the stroma in AP facial skin is characterised by less solar elastosis and collagen VII 
expression and more FRM, increased vascularisation and NMSC as compared to the HP phenotype. 
HP and AP appear to be distinct clinical and histological entities. Further investigation is warranted 
to determine the underlying mechanisms in HP that confer protection against development of NMSC.   
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The wet-wrap method with diluted corticosteroids versus emollients in children with atopic 
dermatitis – a prospective, randomized, double-blind, placebo controlled trial
SR Janmohamed,1 J Gutermuth1 and AP Oranje2 1 Dermatology, University Hospital Brussels 
(UZ Brussel), Brussels, Belgium and 2 KinderHaven, Rotterdam, Netherlands
Atopic dermatitis (AD) can be treated in multiple ways with both local and systemic therapy. In 
children with severe AD wet-wrap therapy (WWT) is a safe option compared to systemic therapy 
with many side effects. WWT is performed in various ways, with or without (diluted) corticosteroids. 
The question remains whether diluted corticosteroids are really necessary, however, a comparative 
study has never been done before. We performed a prospective, multicentre, placebo controlled, 
double-blind, randomized clinical trial. Patients between 6 months and 10 years old with severe 
AD (SCORAD > 40) who were eligible for WWT were asked to participate in this study. Treatment 
consisted of 4 weeks of WWT with either verum (diluted corticosteroid: mometasone fuorate 1:3 
body and 1:19 face) or placebo (petroleum 20% in cremor cetomacrogolis). Both groups were treated 
in the same way: week 1 - apply once daily on the whole body using the fingertip unit method; week 
2-4 - apply once daily on the lesions at 4 consecutive days per week, using the fingertip unit method. 
At d0, d1, d4, d7, d14, and d28 outcome measures (SCORAD, Quality of life scores, and adverse 
events) were gathered. A total of 39 patients were included in the study; after randomization 20 in 
the placebo group and 19 in the verum group. The SCORAD decreased in both groups, but better 
and faster in the verum group (mean difference in SCORAD at all time points = 13.2, p<0.0001). 
Side effects were mild in the verum group: 10x folliculitis and 3x decrease of cortisol level in the 
first week, which returned to normal after a re-check in the second week. In the placebo group we 
observed 2x folliculitis and 2x infected AD. Both groups show an improvement of AD, however, 
the diluted corticosteroids group shows a statistically significant faster improvement, especially in 
the first week of treatment.    
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Allergen specific immunotherapy in atopic dermatitis
A Kapitány,2 S Baráth,1 A Khasawneh,2 G Béke,2 Z Dajnoki,2 Z Káplár,2 A Szegedi2 and 
K Gáspár2 1 Department of Laboratory Medicine, Faculty of Medicine, University of 
Debrecen, Debrecen, Hungary and 2 Division of Dermatological Allergology, Department of 
Dermatology, Faculty of Medicine, University of Debrecen, Derbrecen, Hungary
Atopic dermatitis (AD) is a chronic inflammatory skin disease prone to relapse, having both genetic 
and environmental factors (e.g. allergens) as underlying causes for its development. The use of 
allergen specific immunotherapy (ASIT) has been restricted to insect venom allergy, allergic rhinitis 
and mild extrinsic asthma; however a few contradicting results are available on the use of ASIT 
in AD. Our aim was to analyze the effect of ASIT on clinical and subclinical variables in patients 
sensitized by house dust mite and suffering from both allergic rhinitis and AD. We examined the 
patients clinical (physical status, disease specific questionnaire), immunological laboratory (defining 
regulatory and effector T cells and also blood dendritic cells – flow cytometry; determining serum 
allergen specific IgE levels – ELISA; atopy patch test, prick test) as well as skin barrier (specifying 
Filaggrin mutation – molecular genetics; determining serum TSLP levels – ELISA; measuring TEWL – 
Tewameter) parameters prior to and during the ASIT treatment in comparison with diseased control 
groups. As a result of ASIT the measured clinical and skin barrier variables displayed improvement 
compared to the initial values as well as to the control group, although the differences were not 
significant. However when only patients without filaggrin mutation where compared, the ASIT 
treated patients showed significant improvement in barrier (TEWL) function (38,96+17,42 g/m2h 
vs. 19,97+2,077 g/m2h; p=0,0357). This result predispose that the modified immune status may 
improve the skin barrier in the mild-to-moderate patients without filaggrin mutation. Perhaps this AD 
population may benefit of ASIT. There is an intricate pathogenesis underlying AD, which requires 
a complex approach in therapy. Additionally to the previously described immunological changes 
attributed to ASIT, analysis of other physicochemical barrier parameters is crucial.    
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Interventions for nail psoriasis
C Busard,1 M Pasch,2 S Oudshoorn,1 L Hooft3 and PI Spuls1 1 Academic Medical Center, 
Amsterdam, Netherlands, 2 Radboud University Nijmegen Medical Centre, Nijmegen, 
Netherlands and 3 Dutch Cochrane Centre, Utrecht, Netherlands
In this update of a Cochrane Review we systematically assess the efficacy and safety of nail psori-
asis treatments. The search was updated to November 2014 in Cochrane Skin Group Specialised 
Register, CENTRAL, MEDLINE, Embase, LILACS and ongoing trial registers. Twelve new studies 
(1469 patients) were included making a total of 30 studies comprising 2735 patients. Five biologic, 
3 radiotherapy and 3 topical studies reported statistically significant improvements in nail disease 
severity. Short term improvement was demonstrated for ustekinumab 45 and 90mg vs placebo (resp. 
26.7% and 24.9% vs 11.8%), secukinumab 150mg monthly and early dosing vs placebo (resp. 
10.6% and 19.5% vs -14.4%), superficial radiotherapy vs sham radiotherapy (20% vs 0% nail), 
lindoil vs olive oil (59.3% vs 16.3%) and tacrolimus 0.1% vs no active treatment (56.2% vs 15.5%). 
Medium term improvement was demonstrated for infliximab 5 mg/kg (57.2% vs -4.1%), golimumab 
50 and 100 mg (resp. 33% and 54% vs 0%), certolizumab (58.8% vs 42.4%) and HPCH lacquer 
vs placebo (55% vs 31.7%). For ustekinumab and golimumab long term extension studies indicate 
maintained clinical response during 52 and 256 weeks respectively. A higher incidence of adverse 
events (mild and tolerable) was reported for systemic compared to topical and radiotherapy. In addi-
tion to infliximab and ustekinumab newly introduced biological agents (secukinumab, golimumab 
and certolizumab) have shown to be beneficial in the treatment of nail psoriasis. Radiotherapy for 
psoriasis is not used in common practice. Although the quality of evidence for topical therapy was 
generally poor, most interventions showed some improvements on nail disease severity and could 
be valuable in clinical practice if systemic therapy is not indicated. With the growing amount of 
upcoming clinical trials and the development of new scoring systems, harmonization of outcome 
measures and clinical homogeneity is essential to enhance comparability between clinical trials 
and to improve the body of evidence for nail psoriasis treatments.    
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Stress markers in chronic urticaria
A Ograczyk,1 M Kozlowska,2 A Kaszuba2 and A Zalewska-Janowska1 1 Psychodermatology 
Department, Medical University of Lodz, Lodz, Poland and 2 Dermatology, Pediatric 
Dermatology and Oncological Dermatology Clinic, Medical University of Lodz, Lodz, Poland
It is well known that environmental stressors, including psychological ones, play an important 
role in triggering chronic urticaria and could influence its course. Our study aim was to compare 
selected biological parameters (cortisol and DHEA-S saliva levels and cortisol/DHEA-S ratio - con-
cerned as stress markers) with psychological ones (stress level and quality of life) between chronic 
urticaria patients and controls. The study group recruited at dermatology departments, consisted of 
46 females suffering from chronic urticaria (age range: 21-68 years, mean±SD 44.6±14.2) and 33 
females concerned as our control group (age range: 18-78 years, mean±SD 46.3±14.7). Disease 
duration ranged from 6 weeks to 25 years (mean±SD 3.6 years±5.8 years). The following methods 
were used: Perceived Stress Scale (PSS-10), The Short Form Health Survey (SF-36), and ELISA 
method to assess saliva cortisol and DHEA-S levels.  The statistical significance was set at p<0.05. 
Patients with chronic urticaria presented lower cortisol (z=6.833, p<0.001) and DHEA-S levels 
(z=7.024, p<0.001) in comparison to the control group.The obtained results could be regarded as 
objective confirmation of negative influence of chronic stress in urticaria patients (PSS-10 results are 
compatible with them). Patients with chronic urticaria revealed also worse quality of life (QoL) in 
reference to all SF-36 dimensions, except for bodily pain. The results revealed statistically significant 
correlation between higher DHEA-S level (r=0.39, p<0.01), lower cortisol/DHEA-S ratio (r=-0.36, 
p<0.05) and better physical functioning in patients with chronic urticaria. In this group stress also 
negatively correlated with QoL – with all SF-36 dimensions. Our results confirmed negative role 
of stress in chronic urticaria course which led to worse physical, mental and social functioning. 
Chronic influence of stress was revealed also in biological parameters, which –by definition– are 
regarded as fairly objective methods.    
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Scoring infantile haemangiomas: the Haemangioma Activity Score
SR Janmohamed,1 L De Raeve,1 J Gutermuth1 and AP Oranje2 1 University Hospital Brussels 
(UZ Brussel), Brussels, Belgium and 2 Erasmus MC, Rotterdam, Netherlands
Until recently, scoring systems for infantile haemangioma (IH) activity were lacking. We developed 
the Haemangioma Activity Score (HAS), a simple scoring system for retrospective and prospective 
use, based on colour, swelling, and ulceration. Recently, the Haemangioma Severity Scale (HSS) 
has also been described. The following studies were undertaken to validate the HAS and to compare 
the HAS with the HSS. We validated the HAS with a retrospective observational study of photo-
graphs of IHs. We selected those patients who had clear and representative photographs and had 
a follow-up of at least six months. To assess agreement, the HAS of these n=78 IHs was calculated 
independently at two time points by three physicians. We calculated the intraclass correlation 
coefficients (ICC) of the HAS at t=0 and at t=1. In a prospective interventional study with 54 infants 
with IHs treated with oral propranolol we compared the HAS with the HSS. The HAS and the HSS 
were applied independently by two observers. Mean ICC’s of three observers of the HAS at t=0 and 
t=1 were 0.72 and 0.76, respectively. We noted that HSS scores often remained the same upon 
improvement of the IH and therefore do not reflect severity. HAS scores decreased over time, with 
a dramatic drop in the first week of treatment, reflecting the immediate therapeutic responses. We 
conclude that the HAS is a promising scoring system for scoring the activity of IHs in patients at 
different time intervals. It could be useful in future investigations for examining the activity of IHs 
after various therapies or for following the natural course. We also conclude that the HAS is to be 
preferred over the HSS. Advantages: the HAS can also be used in patients with deep IHs and can 
be used both prospectively with patients and retrospectively on photographs.    
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Correlation between the objective SCORAD by physicians and the objective PO-SCORAD 
by parents/patients in children with atopic dermatitis
SR Janmohamed,1 M van Oosterhout,2 F de Waard-van der Spek,2 J Gutermuth1 and 
AP Oranje2 1 University Hospital Brussels (UZ Brussel), Brussels, Belgium and 2 KinderHaven, 
Rotterdam, Netherlands
A self-assessment rating scale (SAS) is a good tool to assess the fluctuating disease severity and 
quality of life in children with atopic dermatitis (AD). The European Task Force on Atopic Dermatitis 
created an SAS based on the Scoring Atopic Dermatitis (SCORAD) index, called the Patient-Oriented 
SCORAD (PO-SCORAD). In a previous report, the SCORAD correlated well with the PO-SCORAD. 
The subjective parameters (itch and sleep disturbance) of the SCORAD/PO-SCORAD might have an 
unpredictable impact on the final score and therefore the objective SCORAD (the SCORAD without 
the subjective parameters) is also widely used. The aim of our study was to assess the correlation 
between the objective SCORAD and the objective PO-SCORAD. We performed an observational 
prospective study with children aged 0-16 years with AD. At baseline and after 6-8 weeks, objective 
SCORAD was assessed by the physician and patients/parents assessed the objective PO-SCORAD. 
Seventy-five children were included. A good and significant correlation was shown between the 
objective SCORAD and the objective PO-SCORAD: Spearman’s ρ correlation = 0.64 (p <0.001). 
We conclude that the objective PO-SCORAD can be used for the evaluation of fluctuating AD and 
that it correlates well with the objective SCORAD.    
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Pruritus: an under-recognized symptom of small-fiber neuropathies
E Brenaut,1 P Marcorelles,2 S Genestet,3 D Ménard4 and L Misery1 1 Dermatology, 
University Hospital, Brest, France, 2 Pathology, University Hospital, Brest, France, 3 Clinical 
neurophysiology, University Hospital, Brest, France and 4 Neurology, University Hospital, 
Rennes, France
Small fiber neuropathies (SFN) are diseases of thinly myelinated A-δ and unmyelinated C fibers. 
Patient examination is considered the most important for diagnosing SFNs, which is confirmed 
with skin biopsies. SFN are characterized by autonomic and sensory symptoms. Little is known 
about the sensory symptoms. The objective of this study was to evaluate frequency and severity 
of sensory symptoms with a focus on pruritus. A questionnaire was given to patients with a SFN, 
after a positive biopsy, it they filled eligibility and exclusion criteria. Forty-one patients responded 
to the questionnaire (71.9% response rate). Mean age was 61.5 years (range 31-85), there were 
63.4% of women. Main causes of SFN were: Goujerot-Sjögren disease (39.0%), idiopathic (34.1%), 
diabetes (14.6%) and vitamin B12 deficiency (7.3%). The most frequent sensory symptoms were: 
burning (77.5%), pain (72.5%), heat sensations (70.2%), numbness (67.5%), crawling (65.0%), 
stinging (60.0%), electric discharge (59.0%), and cold sensations (57.9%). Pruritus was present in 
68.3% of patients, it tended to appear more during the evening than in the morning, noon or night. 
At its worst, pruritus was intense (7.36/10 on a visual analog scale). Pruritus was localized on the 
limbs in a distal-to-proximal gradient, though the back was surprisingly the most frequent location 
(64%). Worsening factors were fatigue, skin dryness, sweating, hot temperature, and stress. Cold 
water was an alleviating factor. 71% of patients declared to scratch their skin “often” or “very often” 
and it was highly or moderately pleasurable for 48% of patients. Limitations were relatively small 
sample size, retrospective study and based on a questionnaire filled out by patients Pruritus occurs 
frequently in patients with SFNs and should be recognized as a possible presenting symptom of 
SFN by dermatologists.    
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Treatment of scabies, Comparison of oral ivermectin vs. Tenutex emulsion
M Goldust Tabriz University of Medical sciences, Tabriz, Iran (the Islamic Republic of)
Scabies is an itchy skin condition and the treatment of choice is still controversial. This study aimed 
at comparing the efficacy and safety of oral ivermectin vs. Tenutex emulsion for the treatment of 
scabies. 360 were studied. The first group received a single dose of oral ivermectin, and the sec-
ond group received Tenutex. Treatment was evaluated at intervals of 2 and 4 weeks, and if there 
was treatment failure at the 2-week follow-up, treatment was repeated. Single dose of ivermectin 
provided a cure rate of 63.9% at the 2-week follow-up, which increased to 83.3% at the 4-week 
follow-up after repeating the treatment. Treatment with single applications of Tenutex emulsion was 
effective in 44.4% of patients at the 2-week follow-up, which increased to 61.1% at the 4-week 
follow-up after this treatment was repeated. Oral ivermectin is superior to Tenutex emulsion in 
the treatment of scabies.    
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Comparison study of sertaconazole 2 % cream versus naftifine 1% cream in the treatment 
of seborrheic dermatitis
M Goldust Tabriz University of Medical sciences, Tabriz, Iran (the Islamic Republic of)
There are controversies in the treatment of seborrheic dermatitis. This study aimed at comparing the 
efficacy of sertaconazole 2 % cream vs. naftifine 1% cream in the treatment of seborrheic dermatitis. 
Sixty patients suffering from SD were studied. Thirty patients received local sertoconazole 2% cream 
and they were recommended to use the cream twice a day and for 4 weeks. To create control group, 
thirty patients received naftifine 1% cream twice a day for four weeks. At the beginning of referring 
and also 2 and 4 weeks after first visit, the patients were examined by a dermatologist to control 
improvement of clinical symptoms and drug side effects. Patients with moderate SI had the most 
frequency (76.6%) at pretreatment stag with naftifine 1% cream. This is while patients with mild SI 
had the highest frequency (53.3%) at post-treatment stage. In patients received the sertaconazole 2 
% cream, the highest frequency was observed in 80% of cases with moderate SI at pretreatment stage 
while patients with slight SI had the highest frequency (83.3%) at post-treatment stage. Sertaconazole 
2 % cream may be an excellent alternative therapeutic modality for treating seborrheic dermatitis.   
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Sudden onset of painful erythemas/ infiltrated erythematous plaques is an early clinical 
indicator of Helicobacter cinaedi bacteremia
S Shimizu,1 R Moriuchi,1 T Miyauchi,1 Y Hamade,1 T Sakai,2 S Yamamoto,2 A Nagasaka3 and 
H Shimizu4 1 Dermatology, Sapporo City General Hospital, Sapporo, Japan, 2 Hematology, 
Sapporo City General Hospital, Sapporo, Japan, 3 Infectious Disease, Sapporo City General 
Hospital, Sapporo, Japan and 4 Dermatology, Hokkaido University, Sapporo, Japan
Helicobacter cinaedi (H. cinaedi) is a Gram-negative spiral bacillus that inhabits the intestinal 
tracts of mammals. It has been implicated as the cause of human gastroenteritis and bacteremia, 
particularly in immunocompromised individuals. The cutaneous manifestations of H. cinaedi are 
poorly understood. Our previously published case series of 47 patients revealed that 34% of the 
cases were accompanied by skin lesions as the initial manifestation of the disease. To further clarify 
the characteristic cutaneous features associated with H. cinaedi infection, 73 cases (including 26 
new cases) were evaluated in detail. As a result, 30% (22/73 cases) of the H. cinaedi bacteremia 
cases showed cutaneous lesions. Detailed examinations revealed that they all had sudden onset of 
erythemas accompanied by high temperature. The most common cutaneous manifestations of H. 
cinaedi bacteremia were superficial cellulitis, which appeared as painful erythemas or infiltrated 
erythematous plaques on the extremities. This study demonstrates that these skin lesions can be an 
early clinical indicator of H. cinaedi bacteremia in the setting of nosocomial infection.    
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Ordinal regression in the mapping of DLQI scores to EQ-5D utility values: is it plausible?
FM Ali,1 R Kay,3 AY Finlay1 and S Salek2 1 Dept. of Dermatology, Cardiff University, 
Cardiff, United Kingdom, 2 University of Hertfordshire, Hatfield and Institute for Medicines 
Development, Cardiff, United Kingdom and 3 School of Pharmacy and Pharmaceutical 
Medicine, Cardiff University, Cardiff, United Kingdom
The aim of this study was to identify a plausible mapping approach to allow the accurate prediction 
of utility values from Dermatology Life Quality Index (DLQI) scores. Cost-utility analysis data are 
deduced from utility values, which are generated by generic quality of life (QoL)/utility measures 
such as the EQ-5D. These measures are able to produce the index values needed to generate quality 
adjusted life years (QALYs). A literature search was carried out using PubMed to identify studies that 
described QoL scores to utility value conversion techniques. 29 articles were identified describing 
various mapping techniques. The most frequently mentioned method was ‘transfer to utility’ or 
‘regression analysis’. Another method, “direct revaluation”, involves defining health states in the start 
measure which are then assigned weights using direct elicitation methods, such as standard gamble 
(SG). Two less common methods included response mapping and effect size translation. A range of 
statistical techniques used for such a conversion were identified, including ordinary least squares 
(OLS) regression, Tobit regression and censored least absolute deviation (CLAD) estimates. Despite 
giving the highest accuracy, linear regression, the most commonly used modeling method, is only 
likely to produce a line of best fit when the relationship between the dependent and independent 
variables is linear. Mapping is more likely to be successful where there is a conceptual overlap 
between the two measures. ‘Ordinal logistic regression’ is a plausible approach as it recognises 
that the responses of dimensions may be ordered, as in the EQ-5D. A large data set is currently 
being explored which would allow the internal and external validation of the predicted EQ-5D 
responses based on the ordinal logistic regression model and utility values derived from the DLQI.   
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Distribution of post-finasteride syndrome in men with androgenic alopecia
SR Georgescu,1 M Tampa,1 S Pa˘unica˘,1 C Ba˘la˘la˘u,2 V Constantin,2 G Pa˘unica˘2 and I Motofei2 
1 Dermatology, Carol Davila University, Bucharest, Romania and 2 Surgery and Urology, 
Carol Davila University, Bucharest, Romania
In a previous study we found that men taking Finasteride for androgenic alopecia are susceptible to 
develop adverse effects, which are irregularly distributed during therapeutic period on four distinct 
groups. Continuing to monitor these men after treatment cessation, we further investigated if the 
post-finasteride syndrome presents a similar irregular distribution (as prolonged adverse effects), 
or a different distribution (a possible rebound effect). Ninety-four men with androgenic alopecia 
who received treatment with Finasteride (1mg/ day, about a year) were investigated after treatment 
cessation. We recorded the post-therapeutic adverse effects through questionnaires, paying a special 
attention (but not limited) to depressive symptoms (DSM IV criteria) and sexual side effects (IIEF). 
Group A consisted in 19 left handed men (sensitive to male pheromones/ left nostril/ right visual 
hemifield; cognitively with abstract perception and visual-sensation) while the group B consisted 
in 26 right handed men (sensitive to female pheromones/ right nostril/ left visual hemifield; cogni-
tively with abstract sensation and visual-perception). No post-finasteride symptoms were recorded 
in these two groups. Group C consisted in 32 right handed men (dependent by androgens/ right 
visual hemifield) while the group D consisted in 17 left handed men (dependent by estrogens/ left 
visual hemifield). The post-finasteride syndrome was encountered at 6 subjects of group C and at 
2 subjects of group D. According to these data, the psycho-sexual profile of men is able to predict 
not only the finasteride adverse effects (during therapeutic period) but also the post-finasteride 
syndrome. The post-therapeutic symptoms occurs not only in androgenic but also in estrogenic 
group of men, due perhaps to the fact that finasteride interferes with both dihydrotestosterone and 
progesterone metabolism.    
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The post-finasteride syndrome after distinct doses/ affections
I Motofei,1 D Rowland,2 SR Georgescu,3 M Tampa,3 S Pa˘unica˘,3 C Baston,4 C Gingu4 
and I Sinescu4 1 Surgery and Urology, Carol Davila University, Bucharest, Romania, 2 
Psychology, Valparaiso University, Valparaiso, IN, 3 Dermatology, Carol Davila University, 
Bucharest, Romania and 4 Urology, Carol Davila University, Bucharest, Romania
Finasteride administration induces in a subset of men persistent adverse effects, which are encoun-
tered not only during therapeutic phase but also after treatment cessation. We investigated the 
post-finasteride syndrome on two distinct samples, one related to male androgenic alopecia and 
the other with benign prostatic hyperplasia, in order to study if the corresponding manifestations 
and magnitude of post-finasteride syndrome would depend by dose and/ or affection. Ninety-four 
men with androgenic alopecia and sixty-three men with benign prostatic hyperplasia, who received 
finasteride for at least six months and discontinued treatment due to various reasons, were investi-
gated at four months after treatment cessation. The post-finasteride symptoms were recorded through 
a questionnaire, which investigated especially in respect to physical, mental, and sexual adverse 
effects. On our samples, the post-finasteride syndrome after 1 mg/ day (male androgenic alopecia) 
generally consisted in chronic fatigue, weakness, insomnia, depression, anxiety, libido, ejaculation, 
orgasmic disorders and erectile dysfunction. After 5 mg/ day, the post-finasteride syndrome often 
consisted in listlessness, anhedonia, depression, libido disorders, decreased semen volume and 
erectile dysfunction. These results show that the post-finasteride symptoms are relatively similar 
after various doses administered for two distinct affections. However, the post-finasteride syndrome 
seems to present a lesser magnitude on subjects with benign prostatic hyperplasia. On one hand, 
such patients could present a greater tolerance to treatment/ post-therapeutic effects (being a disease 
with greater impact on the health). On the other hand, their age (generally higher, with possible 
implications on lifestyle) could contribute to a better adaptation to these side effects.    
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Gingival hypertrophy to finasteride in male androgenic alopecia
S Pa˘unica˘,1 A Dumitriu,1 SR Georgescu,2 I Pa˘unica˘,3 M Sarbu,2 M Tampa2 and I Motofei4 1 
Parodontology, Carol Davila University, Bucharest, Romania, 2 Dermatology, Carol Davila 
University, Bucharest, Romania, 3 Carol Davila University, Bucharest, Romania and 4 Surgery 
and Urology, Carol Davila University, Bucharest, Romania
Finasteride is a 5-α reductase inhibitor widely used in present for male androgenic alopecia. 
Generally, literature data describes adverse effects which are related to psychiatric (depression), 
genitourinary (erectile dysfunction, libido, ejaculation and orgasmic disorders), endocrine (breast 
enlargement), cardiovascular (palpitations, postural hypotension), dermatologic (rash, pruritus, urti-
caria) and musculoskeletal (asthenia) manifestations. Oral adverse effects are briefly described in 
present or are even neglected. One hundred and two patients taking finasteride (1 mg daily) for male 
androgenic alopecia were monitored in respect to possible adverse effects to this drug. We included 
in this study not only physicians related to the above presented medical specialties/ side effects, but 
also two specialists in parodontology to follow occurrence of possible oral manifestations/ allergies 
to finasteride administration. Prior to finasteride administration, no significant gingivo-parodon-
tal lesions were found. After starting finasteride therapy, the gingivo-parodontal changes were 
encountered in: 8 (erythema), 3 (purpura), 2 (petechiae), 3 (periodontal inflammation), 11 (mucosal 
pallor), and 2 (gingival hypertrophy) subjects. Excepting gingival hypertrophy, all these oral lesions 
were resolved through specific treatments, none requiring stopping the finasteride administration. 
Gingival hypertrophy (that occurred at about three and respectively seven months after finasteride 
administration) necessitated finasteride cessation at both patients, and the lesions regressed totally 
in less than three months. Drug-induced gingival hypertrophy (DIGO) often regresses after treatment 
cessation; we suspect that the two presented patients were affected by DIGO, which means that the 
oral side effects to finasteride administration are currently underestimated.    
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A survey of Japanese atopic dermatitis patients - clinical differences between ”Intrinsic” 
and “Extrinsic” subtypes
S Tokoro,1 K Igawa,1 T Ugajin,1 Y Tokura,2 I Katayama,3 Y Miyachi,4 T Satoh5 and 
H Yokozeki1 1 Tokyo Medical and Dental University, Tokyo, Japan, 2 Hamamatsu university, 
Shizuoka, Japan, 3 Osaka University, Osaka, Japan, 4 Kyoto university, Kyoto, Japan and 5 
National Defense Medical College, Saitama, Japan
Atopic dermatitis(AD) is a heterogeneous disease with epidermal barrier impairment and skin inflam-
mation. Recently, AD is classified into ”Intrinsic AD” with normal serum IgE and “Extrinsic AD” 
with elevated serum IgE. We sought to investigate the clinical differences of Japanese AD patients 
between Intrinsic and Extrinsic subtypes. This study was conducted according to the Declaration 
of Helsinki Principles, performed after obtaining written consent from the patients, and approved 
by the Medical Ethical Committees of each centers. AD patients of each university were enrolled. 
AD was diagnosed by the expert dermatologists according to the Japanese AD guideline and Han-
ifin and Rajka criteria. We requested each centers to fill out questionnaire about clinical feature, 
labatory data, presence/absence of metal allergy (Co,Ni,Cr) and filaggrin gene mutation. Collected 
questionnaire were classified into “Intrinsic AD” group (IgE%200kU/l) and “Extrinsic AD” group 
(IgE>200 kU/l) for analysis. 179 AD patients were enrolled. 21 patients(12% ) were intrinsic AD (5 
male,16 female) and 158 patients(88%) were extrinsic AD (95 male 63 female). Intrinsic AD had 
less asthma and more complications of hand eczema, refractory face erythema and metal allergy, 
whereas extrinsic AD had more complications of erythroderma, dirty neck and prurigo nodularis. 
Contrary to the former studies, incidence of filaggrin gene mutation was higher in the intrinsic 
AD group in this study. Patients with filaggrin gene mutation had more complications of ichtyosis 
vulgaris and palmar hyperlinearity. New target therapy is expected by elucidating both AD groups.   
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Incidence of secondary failure and antibody formation to infliximab in Japanese psoriasis 
patients
E Nishida, R Kubo, A Morita and S Muramatsu Geriatric and Environmental Dermatology, 
Nagoya City University, Nagoya, Japan
Secondary failure of infliximab may develop in the treatment of psoriasis. We examined 102 patients 
treated with infliximab in our hospital and analyzed the association between treatment failure and 
the psoriasis activity severity index (PASI) score at the initial administration, age of onset, disease 
duration, and body weight. Primary treatment failure occurred in 8 patients(7.8%). Maximum effects 
occurred at 22 weeks among all treated patients. Secondary treatment failure occurred in25 patients 
(24.5%) at a mean of 54 weeks after treatment.Effective (non-failure) cases had a PASI score <10, 
were >60 years of age at onset, and were treated within 1 yearof disease onset (p=0.003, 0.04, 
0.007, respectively), suggesting that these factors are important toward preventing secondary failure 
of infliximab. We further analyzed the blood concentration of antibody to infliximab (ATI) in 47 
patients treated with infliximab. Among these 47 patients, 16 (34.0%) exhibited ATI positivity, 
and ATI appeared at a mean of 20.2 weeks (0~38 weeks). ATI levels were measured in 18 of the 
25 patients with secondary failure. Of these 18 patients, 11 (61.1%) exhibited ATI positivity, and 
the ATI positivity occurred at a mean of 15.5 weeks. Furthermore, among the seven patients with 
primary failure in whom ATI was assessed,four patients (57.1%) were ATI-positive. ATI appeared 
relatively early, at 14.5 weeks. Therefore, examination of ATI at an early time-point may predict 
secondary failure in Japanese (Asian) patients.    
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Effects of physical exercise on dermal collagen can be visualized in vivo by nonlinear 
microscopy
K Lorincz,1 D Haluszka,1 A Keszeg,1 A Banvolgyi,1 N Gyongyosi,1 R Szipocs,2 S Kárpáti1 and 
N Wikonkál1 1 Department of Dermatology, Semmelweis University, Budapest, Hungary and 
2 Institute for solidstate physics and optics of Wigner RCP, Budapest, Hungary
It is known that sedentary lifestyle, fat and sugar rich nutrition cause a variety of health risks, such 
as cardiovascular and metabolic diseases. Obesity related type 2 diabetes is characterized as an 
accumulation of visceral and subcutaneous fat and high plasma glucose levels. These lead to 
degradation and rearrangement of extracellular matrix and dermal collagen trough free fatty acids 
and tissue glycation. These are important cofactors of skin related complications such as impaired 
wound healing, ulcers and infections. Lowering glucose levels and fat tissue by physical exercise 
(PE) helps fighting these complications. For this reason we set out to visualize the weight gain and 
weight loss related skin changes by in vivo nonlinear microscopy and ex vivo histology. Mice kept 
on various diets and PE were used in this experiment. One group received ad libitum high-fat diet 
while control group was kept on ordinary chow. Dermal status was assessed at the beginning and 
followed until the end of experiment. After 12 weeks there was a significant weight difference 
between the groups, and after 24 weeks animals in high-fat group reached the plateau of weight 
gain. At this time there was a remarkable difference in dermal collagen content and integrity. After 
starting daily PE the weight of control animals did not increase further. Mice in high-fat group 
showed a significant weight loss after 8 weeks where this tendency stopped. In vivo and in vitro 
analyses revealed a slight amelioration of dermal status. Further weight loss could be achieved by 
changing the diet from high-fat to regular chow in addition to PE. After 10 more weeks average 
weight of mice in former high-fat group reached the weight of control animals and dermal status 
showed a significant improvement. We concluded that beneficial effects of PE on dermal collagen 
can be visualized by nonlinear microscopy, further that changing nutritional habits is indispensable 
for reducing health risks.    
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Deposition of fibrillin-rich microfibrils in photoaged dermis following topical treatment with 
Erés - a novel anti-ageing product
LF Cotterell and RE Watson Centre for Dermatology Research, The University of Manchester, 
Manchester, United Kingdom
Fibrillin-rich microfibrils (FRMs), important components of the cutaneous elastic fibre system, are 
significantly reduced in chronically photoaged skin. Treatment of photoaged skin with topical 
all-trans retinoic acid (tRA) improves its clinical appearance associated with deposition of FRM at 
the dermal-epidermal junction indicative of repair. We investigated the potential of Erés (CG Skin, 
Manchester, UK) - a novel, antioxidant-containing anti-ageing product to induce FRM deposition 
using a 12-day occluded patch test assay, the “Manchester Patch Test Assay”. Volunteers (n=10, 
6F; age 66-81 years) were treated on their photoaged extensor forearms with the novel formulation 
(Erés) and vehicle; an untreated occluded area provided a baseline control. Product was applied on 
d1, d4 and d8 of the assay and occluded; tRA (positive control) was applied to a further site on the 
photoaged forearm on d8. 3mm skin biopsies were taken from all sites on d12 and the distribution 
of FRMs assessed by immunohistochemistry. As with previous studies, tRA induced FRM deposition 
in the papillary dermis of photoaged skin (mean ± SEM; baseline, 1.91±0.13; vehicle, 2.06±0.15; 
tRA, 2.43±0.13; p=0.002). The Erés formulation also produced significant deposition of FRM in the 
papillary dermis (active, 3.12±0.12; p=0.001) to a level that was at least equivalent to that produced 
by tRA. These data indicate that the novel over-the-counter anti-ageing product, Erés, is capable 
of repairing photoaged skin implying that it has the potential to produce clinical improvement.   
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Analysis of Neutropenia with Ixekizumab in 7 Clinical Studies of Psoriasis
B Strober,1 D Ilo,2 A Blauvelt,3 B Pangallo,2 M Veenhuizen2 and J Russell2 1 UConn School 
of Med, Farmington, CT, 2 Lilly, Indianapolis, IN and 3 Ore Med Res Center, Portland, OR
We assessed neutropenia and potential neutropenia-related treatment-emergent adverse events 
(TEAEs) in patients with psoriasis treated with ixekizumab (IXE), an anti-IL-17A monoclonal IgG4 
antibody with high binding affinity. Data were integrated from the induction period of 3 phase 3 
randomized, controlled trials (RCTs; 0-12 weeks [wks]), the maintenance period of 2 of the 3 RCTs 
with a randomized withdrawal design (12-60 wks), and all patients exposed to IXE from 7 psoriasis 
trials (N=4204;4730 patient years of exposure; doses ranging from 5 mg – 150 mg). During the 
induction period patients received IXE every 2 (IXE Q2W; N=1167) or 4 wks (IXE Q4W; N=1161) 
following a 160-mg starting dose, etanercept (ETN, 50 mg biweekly; N=739), or placebo (PBO, 
N=791). The maintenance period included patients re-randomized to IXE Q4W (N=416), IXE Q12W 
(N=408), or PBO (N=402). Neutropenia was graded according to CTCAE criteria. Among all patients 
exposed to IXE, there were 2 discontinuations and no serious AEs related to neutropenia. During 
the induction period, grade 2 neutropenia was observed in 2.1%, 1.9%, 3.3% and 0.3% of patients 
and grade 3 in 0.2%, 0, 0.5% and 0.1% in IXE Q2W, IXE Q4W, ETN and PBO groups, respectively. 
There was 1 case of grade 4 neutropenia in IXE Q4W; this patient’s neutrophil count was within 
normal range 2 days later. In maintenance, grade 2 neutropenia was noted in 1.9%, 1.2% and 1.2% 
of IXE Q4W, IXE Q12W and PBO patients, respectively; grade 3 neutropenia was observed in 1 
patient receiving IXE Q12W. Among all patients exposed to IXE, grade 2 neutropenia was observed 
in 2.8%, grade 3 in 0.2%, and grade 4 in 2 patients (the patient mentioned above and a patient who 
later returned to grade 2 on treatment). Neutrophil changes were transient, with counts recovering 
after continuous IXE treatment. Only 1 patient had an infection (nasopharyngitis) with an onset date 
≤14 days before grade 3 neutropenia was noted. In patients treated with IXE, low-grade neutropenia 
was uncommon and grade 3 or worse neutropenia was rare.    
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Support for the hypoxia theory in the pathogenesis of infantile haemangioma
SR Janmohamed,1 T Brinkhuizen,2 J Gutermuth,1 AP Oranje3 and M van Steensel2 1 
University Hospital Brussels (UZ Brussel), Brussels, Belgium, 2 Maastricht University Medical 
Center, Maastricht, Netherlands and 3 Erasmus MC, Rotterdam, Netherlands
The pathogenesis of infantile haemangioma (IH) remains unknown. Endothelial cells play a role but 
it is unknown why they grow rank. Several mechanisms have been proposed, including hypoxia, 
which triggers up-regulation and stabilisation of hypoxia-inducible factor 1α (HIF1α). HIF1α stim-
ulates downstream transcription of target genes that enhance angiogenesis. Hypoxia seems to play 
an important role: local ischaemia (an anaemic macula) can be seen in almost 50% of IH cases as a 
so called precursor lesion. In this study we aimed to identify possible involvement of hypoxia in the 
pathogenesis of IH, as hypoxia signalling constitutes a potential therapeutic target. IH tissue samples 
collected from 1991-2011 (preserved in paraffin) were immunohistochemically analysed for HIF1α 
and its known targets: BNIP3 (BCL2/adenovirus E1B kD-interacting protein (BNIP) family member 
3), CA-IX (Carbon Anhydrase IX), GLUT-1 (Glucose Transporter 1), pAKT (Phosphorylated protein 
kinase B), pS6 (Phosphorylated S6 protein), and VEGF (Vascular Endothelial Growth Factor). Four 
observers independently assessed findings. Two of the 10 IH samples appeared to be in the growth 
phase. GLUT-1, BNIP3, pAKT, and VEGF were positive in all samples. pS6 was positive in nine cases 
and negative in one. CA-IX was weakly positive and HIF1α was negative in all cases. We conclude 
that several factors implied in hypoxia-induced angiogenesis may be involved in IH development. 
Prospective studies are needed to conclusively determine which factors involved in the hypoxia 
cascade are required for an IH to grow and can thus possibly be targeted by drugs for IH treatment.   
237
Simplified Method to Assess the Body Surface Area Involvement in Vitiligo
N van Geel,1 M Bekkenk,2 A Wolkenstorfer,2 A Lommerts,2 V Eleftheriadou,3 K Ezzedine4 
and R Speeckaert1 1 Dermatology, Ghent University Hospital, Gent, Belgium, 2 Dermatology, 
Academic Medical Center, Amsterdam, Netherlands, 3 Centre of Evidence Based 
Dermatology, University of Nottingham, Nottingham, United Kingdom and 4 Department of 
Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Disorders, 
Bordeaux, France
In general the clinical assessment of vitiligo incorporates an estimation of the involved body surface 
area (BSA). The most commonly used method is the “rule of nines” or the “palm of hand 1% rule”. 
The estimation is subjective and sensitive for over- or underestimation. Moreover, it has a learning 
curve and can be challenging and time-consuming. In this study we evaluated a new tool in a 
preclinical validation stage to assess the BSA involvement of vitiligo. Our objective was to evaluate 
the inter-rater and intra-rater reliability of a simplified method to assess the BSA involvement in 
vitiligo. Five dermatologists (including 1 trainee) evaluated clinical pictures of vitiligo patients. 
For the first assessment round they were asked to use the palm of hand 1% rule (method 1; clin-
ical pictures of 20 patients). The second round was performed with the help of the new scoring 
template after receiving a short (5 minutes) training (method 2; clinical pictures of 31 patients). 
This template included clinical pictures of 8 body locations reflecting 6 degrees of involvements. 
Method 1 demonstrated a good inter-rater reliability (interclass correlation for BSA 0.885; 95% CI: 
0.817-0.936). With method 2 the inter-rater reliability was further improved to excellent (interclass 
correlation 0.933; 95% CI: 0.912-0.950). In addition, a clear improvement of user friendliness was 
achieved with the second method. This simplified method provides a useful tool for the assessment 
of the BSA involvement in vitiligo. The possible advantages of this tool in terms of standardization, 
applicability as a patients reported outcome, user friendliness, minimal detectable changes and 
rapidity in use compared to the palm of hand 1% rule are currently evaluated more in detail in an 
ongoing second part of this study.    
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Alcohol Consumption and Psoriasis Severity- a Prospective Study in Sweden
L Zou,1 E Bircan,2 A Helander,4 K Stokkeland,3 J Franck5 and K Nordlind2 1 Department 
of Dermatology and Venereology, Södersjukhuset, Stockholm, Sweden, 2 Department of 
Medicine, Dermatology and Venereology Unit, Karolinska Institutet, Stockholm, Sweden, 
3 Department of Medicine, Gastroenterology and Hepatology Unit, Karolinska Institutet, 
Stockholm, Sweden, 4 Department of Laboratory Medicine, Karolinska Institutet, Stockholm, 
Sweden and 5 Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, 
Sweden
Higher than average alcohol use has been reported among individuals with psoriasis. In a previous 
cross-sectional study we found a correlation between extent of psoriasis and alcohol use. A pro-
spective study was carried out, to register among females, the alcohol use and psoriasis severity over 
time. The study was carried out during a time period including Christmas and New Year, since the 
alcohol consumption was expected to rise during this period. Twelve females with psoriasis and 
regular alcohol use were recruited from dermatology and psoriasis clinics in the Stockholm county 
area. Patients on systemic treatment and phototherapy were excluded. The patients were requested 
to register in a calendar their daily use of alcohol and estimate the severity of psoriasis weekly, using 
self-administered psoriasis area severity index (SAPASI), over a period ranging from 8 to 12 weeks. 
Psoriasis area severity index (PASI) and an alcohol biomarker, serum phosphatidylethanol (PEth), 
were measured at three visits during this period. Friedman test was used to calculate the difference 
of alcohol use over time. The alcohol consumption previous to PASI and SAPASI measurements 
was correlated using linear regression. The majority of patients had mild psoriasis (median range 
of PASI 3.7-4.3) and consumed low to moderate amounts of alcohol (median range PEth 0.1-0.15). 
The use of alcohol was significantly higher during week 52 and 1 (Christmas and New Year period) 
in comparison to week 3 and 4. No correlation was found between alcohol use and SAPASI and 
PASI measurements. In females with mild psoriasis and low to moderate consumption of alcohol, 
the alcohol use previous to registration of PASI and SAPASI did not correlate with the registered 
disease severity.    
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Potential role of infections behind inefficacy of anti-TNF-α treatment of psoriasis
K Herszényi,1 D Papp,1 K Polgár,1 H Jókai,1 N Wikonkál,1 D Inotai,2 A Tordai2 and P Holló1 
1 Semmelweis University, Budapest, Hungary and 2 Hungarian National Blood Transfusion 
Service, Budapest, Hungary
Associations between infections, guttate exacerbations and genetic background in anti-TNF-α bio-
logicals treated psoriatic patients were investigated in this retrospective study. 190 patients with 
severe psoriasis were enrolled. We registered acute and chronic infections and switches between 
biologicals. HLA-Cw6,-Cw2 haplotype as genetical predisposing factors were also determined. 
Those patients who needed a switch of anti-TNF-α treatment, showed significantly higher occur-
rence of acute infections - mostly of the upper respiratory system-, chronic infections and guttate 
exacerbations. HLA-Cw6 allele was significantly more frequent in psoriatic patients, compared with 
Hungarian normal population. There was no significant correlation between HLA-Cw6 allele and 
the therapeutic response. Strong tendency was found towards statistical significance for no need for 
switching the therapy in case of HLA-Cw2. We demonstrated, that acute or chronic infections may 
be one causative factor of inefficacy and switch of anti-TNF-α biologicals, often manifestating as 
guttate exacerbations of skin signs. Before starting and during biological therapy, infections should 
be diagnosed and healed preciously.    
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The decrease of IL-34 is the key mechanism to provoke the disappearance of Langerhans cell 
in the skin lesion of pellagra
S Yamaguchi, H Uezato and K Takahashi Dermatology, University of the Ryukyus, Okinawa, 
Japan
The pellagra patients present with severe skin dermatosis including vacuolization and necrosis of 
keratinocytes after the prolonged inflammatory reaction. We previously reported the loss or com-
plete depletion of Langerhans cells in the lesional epidermis of pellagra patients depending on the 
degree of the histological severity. The reason, why Langerhans cell disappeared by the deficiency 
of nicotinic acid, is not yet understood, and we cannot answer certainly if the disappearance of 
Langerhans cells observed in pellagra are to be the cause or effect of the characteristic prolonged 
inflammation. IL-34, TG-Fb1, GM-CSF, BMP7 and TSLP are known to be factors to recruit or 
maintain epidermal Langerhans cell. In this study, we had a chance to examine the expression of 
these trophic factors for Langerhans cell, and also to analyze the presence of Langerhans cell in 
both lesional and non-lesional skin of a severe pellagra patient. IL-34 was significantly decreased 
in the pellagra skin, while other factors was not altered. We could further observe the cross section 
covering the severe inflammatory lesion and adjacent normal skin. Langerhans cell was completely 
disappeared in the lesional pellagra skin; on the contrary, Langerhans cell survived and its amount 
was sustained in the close normal region. From these observations, we thought that the disappear-
ance of Langerhans cell was the consequence of the disturbance of the recruitment from bone 
marrow. After the prolonged inflammation in pellagra, the expended Langerhans cells cannot be 
compensated due to the shortage of the trophic factor IL-34, and resultantly the epidermis lacks 
the Langerhans cells in pellagra.    
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Psychological aspects of chronic dermatological patients- potential supporting therapy
AE Platkowska, A Ograczyk, Z Gerlicz-Kowalczuk, Z Kabzinska and A Zalewska-Janowska 
Psychodermatology Department, Medical University of Lodz, Lodz, Poland
The aim of the study was to evaluate stress coping strategies and level of both self-efficacy and 
the anxiety as exponents of social functioning in a group of dermatological patients. The research 
group comprised 48 patients (34 females and 14 males) suffering from different skin diseases Acne 
(50%), Atopic Dermatitis (16,66%), Eczema( 16,66%), Aloplecia (6,25%) and Psoriasis (8,33%) of 
the out-patient psychodermatology clinic. The average age was 32.13 ± 15.77(range 14 – 72 ) and 
the mean disease duration was 9 years 1 month ± 9 years 5 months. Methods used : 1. Author`s 
questionnaire covering clinical and demographic data; 2. CISS – Coping Inventory for Stressful 
Situations (Endler, Parker) to measure stress coping styles; 3.STAI – State-Trait Anxiety Inventory 
(Spielberg et al) – to evaluate anxiety as a temporary state and as a constant internal disposition; 
4.GSES - The General Self-Efficacy Scale (GSES, Watson, Greer) Statistical significance was set at 
p<0.05 The correlations between disease duration and stress coping style concentrated on avoiding 
and its subtype – looking for social contacts were found (r=-0.36). The longer patients suffered from 
their diseases, the more often they avoid thinking about and experiencing stressful situations, and 
less frequently searched for social contacts. Higher anxiety as a state (r=-0.30) and as a trait (r=-
0.49) were associated with lower self-efficacy. Participants who experienced higher anxiety level 
as an internal disposition less frequently looked for social contacts (r=-0.31). The results suggest 
that anxiety may be the cause of withdrawal from social interactions. This information incline that 
introduction of interventions that reduce anxiety could be beneficial for a patients, perhaps would 
colerate with the increase in self-efficacy, better physical, social and psychological functioning. 
Above observations tend to conclusion that psychological intervention could be one of the factors 
withch may have a positive impact of the disease course and treatment.    
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Stress and skin diseases in inflammatory bowel disease patients
A Kepska-Nawrocka,2 M Wisniewska-Jarosinska1 and A Zalewska-Janowska2 1 
Gastroenterology Clinic, Medical University, Lodz, Poland and 2 Psychodermatology 
Department, Medical University, Lodz, Poland
Inflammatory bowel diseases (ulcerative colitis and Crohn’s disease) are characterized by chronic 
course of the disease, distressing symptoms, necessity of long treatment and uncertain prognosis. 
These factors result in high stress level and negatively affect mental state. As numerous studies show 
that stress negatively affect course of inflammatory bowel disease, skin condition, course of derma-
tological diseases and even cause their first onset, the aim of the study was to assess chosen stress 
parameters in people with inflammatory bowel disease group and control group, and to determine, 
if stress causes skin disorders in these groups. There were 31 inflammatory bowel disease patients 
recruited for the study (58% males and 42% females, mean age ±SD 37±11,6 years, mean disease 
duration ±SD 74±100). Control group consisted of 30 people without inflammatory bowel diseases 
(53% males, 47% females, mean age ±SD 40 ±17,4). Both groups were examined dermatologically 
and completed Perceived Stress Scale and Social Readjustment Rating Scale. The study group com-
pleted Inflammatory Bowel Disease Questionnaire. There were no differences in perceived stress 
and exposure to stressful life events between groups (p>0,05). There were no associations between 
stress parameters and bowel disease duration or diarrhea frequency change during month preceding 
the study (p>0,05). Results of both stress measuring scales correlated with low life quality (p<0,05). 
Inflammatory bowel disease patients noticed link between skin and intestine condition. They had 
skin diseases more frequently than control group, mainly allergic ones (p<0,05). People from both 
groups noticed connection between stress and skin condition. In both groups link between stress 
parameters and skin diseases was observed, but it was not statistically important (p>0,05). These 
results suggest the necessity of holistic care of various specialists- dermatologists, psychiatrists and 
psychologists over inflammatory bowel disease patients.    
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The effect of extracorporeal shock wave therapy on wound healing and quality of life in 
patients with chronic ulcers
G Leemans, SR Janmohamed, S Baharlou and J Gutermuth Dermatology, University Hospital 
Brussels, Brussels, Belgium
Chronic ulcerations are a major healthcare problem with important medical, social and financial 
consequences. Their management is complex and they often do not heal despite the availability of 
many wound care products. Some recent studies suggest that extracorporeal shock wave therapy 
may be effective in the treatment of chronic ulcers, but the exact underlying mechanisms are not yet 
fully understood. This study evaluates the safety of shock wave therapy and the effects on wound 
healing and quality of life in patients with chronic ulcers. Ten patients with chronic, non-improving 
ulcers were prospectively enrolled between December 2014 and March 2015. Treatment consisted 
of regular wound care and extracorporeal shock wave therapy (C-wave+, Ortho Medico) at 500-
1000 impulses/cm2 at energy level E2-4, once or twice a week during four sessions, depending on 
wound size and etiology. Evaluation included clinical assessment of the ulcer status with photo 
documentation, bacteriological and hematological examination, a Dermatology Life Quality Index 
questionnaire and pain scores according to a Visual Analogue Scale. We observed a mean decrease 
in wound surface of 71 % and in wound depth of 60% six weeks after the first treatment session. 
Patients had 43 % less exsudative wounds and an increase of 50 % of bacterial colonization was 
seen. The quality of life improved significantly after treatment with 60 % and VAS-scores decreased 
significantly with 38 %. Three patients had side effects: mild pain, oedema and superficial hema-
toma, all disappearing spontaneously after 24 hours. Extracorporeal shock wave therapy seems to 
be effective and safe in the treatment of chronic ulcers. Further research is necessary to understand 
the underlying mechanisms and to create treatment protocols.    
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Sublingual immunotherapy efficacy in patients with atopic dermatitis in Korea
J Lee, J Roh and H Ryu dermatology, Gilhospital, Incheon city, Korea (the Republic of)
Atopic dermatitis (AD) is currently regarded as an allergic inflammatory disease. Many studies 
have shown AD to have multiple causes that activate complex immunological and inflammatory 
pathways. However, aeroallergens, and especially the house dust mite (HDM), play a relevant role 
in the elicitation or exacerbation of eczematous lesions in many AD patients. Accordingly, aller-
gen-specific immunotherapy has been used in AD patients with the aim of redirecting inappropriate 
immune responses. Sublingual immunotherapy (SLIT) is especially preferred because of its easy 
application and safety. The aim of this study was to describe the effect of SLIT in patient with AD. 
Patients with AD who allergic to HDM were evaluated. Patients who allergic to HDM have been 
treated with SLIT for over 1yr. The effect of patients on clinical course of SLIT with Dermatophagoi-
des pteronyssinus and Dermatophagoides farinae in a standardized extract was assessed and the 
side effect of SLIT were recorded. The records of 20 patients (13 males and 7 females) were studied. 
The mean age for starting SLIT was 16.3 years (aged 6-36 years, median age 13years). Treatment 
was deemed effective or very effective in 70% of the patients. The majority of the patients were 
satisfied with their treatment, which was well tolerated. There were no serious side effects except 
transient nausea, abdominal pain and oral itching sensation in the first few days. SLIT had to be 
discontinued in 2 patients (10%) because of exacerbation of asthma and dermatitis. Especially, the 
compliance of patients with AD and allergic rhinitis were better than patients with AD only. SLIT 
reduces symptoms of AD, the amount of drug consumption and the progression of the disease. 
Especially, SLIT is recommendable to patients with AD and allergic rhinitis. We believe SLIT can be 
an alternative, safe treatment option for allergic AD refractory to long-term conventional treatment.   
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The prevalence of cardiovascular risk factors of comorbidities in patients with psoriasis in 
the Czech Republic
J Votrubova, K Juzlova, M Dzambova and J Hercogova Dermatovenereology, Bulovka 
Hospital, Prague, Czech Republic
Psoriasis is a chronic inflammatory skin disease, the prevalence of which is around 1.5 % to 4.7% in 
Europe and in the USA. Many studies have already demonstrated that the prevalence of metabolic 
syndrome, atherosclerosis is significantly higher in psoriatic patients than in the common popula-
tion. The results of published studies are highly variable and the conclusions are ambiguous. No 
similar study has been performed yet in the area of Czech Republic. We therefore initiated a project 
aimed at identifying the presence of risk factors and early stages of selected diseases that represent 
important comorbidities. The study was designed as a hospital-based case-control study. Patients 
with chronic plaque psoriasis were enrolled as cases. The control group, selected based on a ratio 
of 1:2, was composed of patients with other skin diseases who complied with the same restrictive 
criteria used in cases. The results of the study are coherent and consistent with the current level of 
knowledge. They indicate that psoriasis predisposes the patients to hypertension, a higher level of 
BMI and a decreased level of HDL cholesterol. These parameters have been clearly demonstrated 
as risk factors for the development of cardiovascular diseases. The associations among psoriasis 
and diastolic blood pressure, BMI value, LDL cholesterol are statistically significant in the binary 
data logistic model as well. The dispensary care for psoriatic patients should focus especially on 
secondary prevention of predisposing diseases.    
